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ABSTRACT 
The overall goal of this thesis was to determine whether optical tomographic 
imaging can be employed to predict treatment outcome in women with breast cancer (BC) 
who undergo neoadjuvant chemotherapy (NACT). NACT is widely applied as a standard 
treatment for patients with newly diagnosed operable invasive BC.  Only about 13-30% 
of women have a response to this treatment.  Furthermore, NACT is an expensive and 
toxic treatment that takes several months to completely administer.  In order to know the 
response of the patient, physicians usually need to wait until the months of NACT has 
finished and the patient has undergo surgery in which they receive the pathology.  If the 
long-term treatment response could be predicted early into the treatment regimen, the 
patient would be relieved of any unnecessary side effects and alternative treatments 
could be initiated.  We have used a novel dynamic DOT system to study the effects of 
targeted NACT. Unlike X-ray imaging, which requires potentially harmful ionizing 
radiation, DOT can be applied without side effects, which is particularly important in the 
case of multiple imaging sessions to be performed over the course of treatment.  We have 
tracked 40 subjects and imaged them at 6 different time points during their NACT.  For 
this study, two different types of data were collected: static (single 3D image) and dynamic 
(3D movies).  The combination of the data may be used to accurately determine the 
response of the patient.  With non-invasive, non-ionizing DOT imaging we have been able 
to determine within two weeks if the patient will respond to treatment with an accuracy as 
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CHAPTER 1: INTRODUCTION        
1.1 Overall Goal and Specific Aims 
The overall goal of this thesis is to determine whether optical tomographic imaging 
biomarkers can be employed to predict treatment outcome in women with breast cancer 
(BC) who undergo neoadjuvant chemotherapy (NACT). BC affects 1 in 8 women in their 
lifetime. In the United States, there are approximately 230,000 women with invasive BC 
and almost 40,000 die every year. NACT is widely applied as standard treatment for 
patients with newly diagnosed invasive BC.  The goal of NACT is a pathologic complete 
response (pCR) at definitive surgery which typically is performed at ~6 months after 
treatment initiation. A pCR is associated with a substantial increase in 5-year survival and 
reduction in distant metastatic recurrences.  However, a pCR is achieved in only 15-40% 
of women.1-3 Furthermore, NACT is an expensive and toxic treatment that takes several 
months to completely administer, and major efforts are underway to find new drugs that 
increase pathologic response and ultimately improve survival.   If the long-term treatment 
response could be predicted early into the treatment regimen, unnecessary side effects 
could be minimized, and alternative treatments could be initiated. 1, 3  
Diffuse optical tomography (DOT) has the potential for becoming an early 
outcome-prediction tool. Over the last decade, DOT has been shown to be very sensitive 
to vascular changes in BC and other diseases. As a result, several groups have started 
to study NACT monitoring using DOT.  However, so far the patient-enrollment numbers 
have been relatively small and the few patients that participated in these studies have 
received a wide variety of different NACT regimens. Since the different drugs may affect 
the optical signals in different ways, the studies might have confounding results.  
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Furthermore, none of the previous studies have involved a full tomographic imaging 
system that images both breast at the same time, and very few studies have looked at 
hemodynamic changes in the tumor bearing breast.   
 To overcome the limitations of these previous studies, I had proposed to employ a 
novel dynamic DOT system to study the effects of targeted NACT. Unlike any other optical 
breast imager, this system provides full three-dimensional tomographic images of both 
breasts simultaneously.  Furthermore, the system allows for the study of static and 
hemodynamic effects, which is achieved through relatively fast data acquisition frame 
rates. The goal was then to use the system to perform the largest clinical pilot study to 
date and only enroll patients that are on the same standard NACT regimen.  To test and 
evaluate the potential of DOT imaging in the NACT setting, I have completed the following 
4 aims. 
 
Specific Aim I: Performed a 40-patient clinical NACT-monitoring study to 
demonstrate that 2-week changes in DOT-derived imaging biomarkers 
corresponds with pCR 
Challenge: To determine if DOT can predict treatment response of breast tumors to 
NACT. 
Approach:  We have previously built and utilized a DOT system to image subjects with 
malignant and benign tumors, as well as, healthy breast tissue. We found that biomarkers 
such as oxy-hemoglobin [HbO2], deoxy-hemoglobin [Hb], and total hemoglobin [HbT] 
concentrations, as well as their dynamic responses to a breath-hold, can be used to detect 
tumors. Employing the same system in this monitoring study, I hypothesized that these 
   3 
 
biomarkers will change substantially at the beginning of the treatment and indicate if a 
patient will obtain a pCR. 
Impact: Finding imaging biomarkers that can predict treatment outcome early on, will help 
physicians in designing more effective treatment strategies.  
 
Specific Aim II: Developed a pre-processing and post-processing protocols for 
analyzing “static data” acquired from NACT imaging and to monitor how different 
chromophores change over the course of treatment. 
Challenge: Artifacts at the tissue-air interface are very common in optical images and 
therefore can effect automated quantification.  Additionally pre-processing and post-
processing must be similar for all imaging time points. 
Approach: Created custom algorithms via MatLab to pre-process data, to extract volume 
geometries that contain the tumor region, and to track the region of interest over time. 
Impact: The static data shows absolute concentrations of hemoglobin and water fraction.  
Observations of these parameters show changes over time for subjects that have a good 
or partial response to treatment, and can be used to monitor treatment. 
 
Specific Aim III: Develop a pre-processing and post-processing protocol for 
analyzing “dynamic data” acquired from NACT imaging.   
Challenge: We can collect dynamic information over time, and are able to view the 
hemodynamic changes in the breast when a stimulus is applied (e.g. a 30-second breath 
hold).  Therefore the challenge lies in how to use an intrinsic contrast to see tumor 
response. 
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Approach: Extracted features from dynamic breath hold images to determine different 
hemodynamic qualities of the vasculature of the tumor. 
Impact: The dynamic optical imaging can show how blood flow changes in the tumor 
region during NACT. 
 
Specific Aim IV: Combined static and dynamic data analysis schemes for 
discriminant analysis, which can be used to find a combination of imaging 
biomarkers that most accurately predict tumor response to NACT. 
Challenge: Finding effective combination of physiological parameters that describe the 
response of the tumor and can distinguish response. 
Approach: Used promising metrics from both the static and dynamic analyses to perform 
linear or quadratic discriminant analysis. 
Impact: Determining a way to predict tumor response accurately using optical imaging. 
 
1.2. Breast Cancer Epidemiology 
The chance of a woman in the United States being diagnosed with breast cancer has 
increased to 1 in 8 (12.3%) from 1 in 11 women since the 1970’s.  The increase in 
prevalence is likely caused by several environmental factors that have change in the 
United States over the past 40 years.  Some of these factors include the increase in 
obesity, increase life expectancy, changes in reproductive patterns (women having 
children at later ages), increase breast cancer screening, etc. Another factor for the 
increase in breast cancer cases may simply be the increase in breast cancer screening 
between 1979 and 1987. 4  The estimated number of incidences for 2014 is 232,670. The 
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number of new cancer cases has increased by 14% since 2000.  Accordingly, the number 
deaths caused by breast cancer in 2014 has also increased and is estimated to be about 
40,000 deaths or 6.8% of all cancer deaths.5  However, as seen in Figure 1, the incidence 
and mortality rate can be very dependent on the race and ethnicity of the individual.  There 
is usually a higher incidence of breast cancer in the non-Hispanic White population, yet 
the mortality rate is the highest among African Americans.4    
 
Figure 1.1 Female Breast Cancer Incidence and Mortality Rates by Race* and 
Ethnicity, US, 2006-2010.4 
 
The overall 5-year survival rate is about 89% among all populations in the United 
States.4, 5  Yet, the 5-year survival rate can vary between 78.9% and 92.8% depending 
on race.  As seen in Table 1.1, Asian women have the highest 5-year survival rate, while 
the African American population tends to have lowest survival rate. African American 
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women tend to be diagnosed with more aggressive cancers that have poor prognosis.  
Also, there are lower 5-year survival rates among populations that have low incomes, 
which prevent them from receiving the medical attention they require.  Since in low income 
subgroups, there may be the lack of health care or funds to receive proper treatment.4 
 
Table 1.1 Five Year Cause Specific Breast Cancer Survival by Race 2003-2009 
*Survival rates are based on patient diagnosed between 2003 and 2009 and folled 
through 2010.4 
Race 5-year Survival Rate 
Non-Hispanic White 88.6% 
African American 78.9% 
Hispanic 87.0% 
Asian 91.4% 
Pacific Islander 86.8% 
 
 
The stage of the cancer can affect the 5-year survival rate of the woman.  Usually, 
when breast cancer is caught in its earlier stages, then the prognosis of the patient is 
much better.  Therefore, as seen in Figure 2, localized cancer cases have the highest 5-
year relative survival.  While, distant or metastatic cancer usually has a poorer prognosis 
and a lower survival rate.5  
 
 
Figure 1.2 Five-year Relative Survival based on Stage of Disease5 
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 Since the 1980’s, the decrease in mortality rate has been contributed to increase 
screening using mammography (MG).  However, in 2010, 51% of women over the age of 
40 received a MG in the last year and 61% of women received a MG in the past two years.  
Additionally, this percentage changes depending on income and age.  For non-poor 
women between 74%-83% received a MG within the last two years. While only 46%-57% 
of women who are poor or near-poor received a MG in the past two years.4  Therefore, 
there is a clinical need to decrease the cost BC screening in order to increase the number 
of women who routine screening.   
 There are other factors that can prevent BC screening.  I have spoken to women 
over the past 5 years about the process of breast cancer screening and treatment and 
many have communicated their dislike of various imaging modalities.  Some women 
refuse to get MG imaging done because the compression is too painful.  Other women 
have said that they are afraid that the radiation will cause breast cancer in the future.  
Some women have refused MRI because they are uncomfortable or claustrophobic.   
Despite the risk of a having BC, many women still refuse to undergo the recommended 
procedures for tumor detection or monitoring.  Hence, BC imaging has other facets that 
need improvement to encourage women to get routine screening. 
 
1.3 Breast Cancer Pathology 
 Breast tissue is mostly consistent of adipose, fibrous, and glandular tissue.  Each 
breast has about 15-20 lobes, which each has up to 40 lobules.6, 7  The lobules are further 
divided into 10-100 alveoli, which secrete milk.  The alveoli are connected to a lactiferous 
tubule, which is connected to a lactiferous duct.  These ducts are basically conduits that 
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bring milk from the milk producing cells to the nipple.  Last, the glandular complexes are 
surrounded by adipose tissue.6 
 
Figure 1.3 Basic anatomy of the breast.6 
 
  
Breast cancer typically originates in either the lobules or the ducts of the breast.  
The four most common types of breast cancer are invasive ductal carcinoma (IDC), 
invasive lobular carcinoma (ILC), ductal carcinoma in situ (DCIS), and lobular carcinoma 
in situ (LCIS).  DCIS originates in the duct of the breast, while LCIS originates in the 
lobules.  In situ type cancers arises when abnormal cells grow and proliferate within the 
ducts or lobules without invading the basement membrane.8   IDC occurs when tumor 
cells have invaded the basement membrane.  Therefore DCIS is often a precursor for 
IDC.8, 9  Similarly, ILC occurs when infiltrates the stroma of the breast and happens to be 
much more difficult to detect.8 
Cancer, in general, starts in an avascular stage where the tumor will grow to 
between 1-2 mm and then reach an equilibrium of growth and apoptosis.  Tumors cannot 
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grow more than a couple millimeters without some conduit to receive nutrients.  Hence, 
tumors need to recruit blood vessels in order to progress.  Hypoxia in the tumor region 
can also induce these new blood vessels.10   
Tumor angiogenesis is much different from normal physiological angiogenesis.  
Tumor blood vessels are irregularly shaped, dilated, have dead ends, and have increased 
permeability.10  Also, blood vessels in the tumor are poorly organized, are compressed 
by surrounding tumor tissue, and provide limited delivery of oxygen and nutrients, and 
have irregular blow flow.11  Additionally, the blood vessels are forced apart due to the 
growing tumor, which can prevent proper drug penetration.11 
 
1.4 Breast Cancer Imaging 
 There are several different methods for imaging breast tissue and identifying 
breast cancer.  Traditional methods include X-ray mammography (MG), ultrasound (US), 
magnetic resonance tomography (MRI), and positron emission tomography (PET).  
However, there have been experimental imaging modalities that have been developed, 
such as optical imaging (OI).  To better understand how OI can be utilized in the clinic, 
we must examine the imaging modalities that currently exist and how these methods are 
being utilized in the breast cancer setting. 
1.4.1 X-ray Mammography 
 Over the last 25 years, the gold standard for breast cancer detection has been X-
ray mammography (MG). In the late nineties, there have been some reports of a ~25% 
reduction in breast-cancer mortality; More recent studies done in 2012 showed a 
reduction between 7%-23% in Europe and Canada over the last couple of decades.12, 13 
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In general this drop has been attributed to an increase in screening over the previous 
decades.  However, it should be noted that during the same time period there has also 
been an increase in adjuvant chemotherapies which, some argue, may have contributed 
to two thirds of the mortality rate decrease.14  Yet another major study done in Canada 
suggested that MG has no effect on the mortality rate, and overall there seems to be no 
clear consensus about the advantages and disadvantages of X-Ray imaging in breast 
cancer detection .15  
While there are conflicting results about the effect of MG on the mortality of breast 
cancer patients, there is no doubt about the diagnostic capabilities of X-ray imaging. 
According to the United States screening program MG has a sensitivity of 75%. The 
sensitivity decreases to 30%-40% with a false negative (FN) rate of 4%-34% for women 
with denser breasts. 12, 13   Therefore, MG is currently suggested for women over the age 
of 40 years, since the sensitivity of MG increases as breast density decreases with age 
and a postmenopausal status.12, 16 
The general guidelines suggest that women between the ages of 40-49 receive 
biennial MG screenings, while women between the ages of 50-74 should receive annual 
screenings. 12, 13   In the state of New York screening coverage laws allow baseline 
imaging at 35-39 years of age and every year over the age of 40 or with a physician 
recommendation.  Insurance coverage for MG screening varies from state to state within 
the United States.17 
1.4.2 Ultrasound 
 In general, US is not recommended as a screening tool and is usually not covered 
by insurance.  Yet, US is employed as an adjunct imaging method to MG. Also US is 
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considered if the patient is at high risk and cannot tolerate MRI, or if they have an 
intermediate risk with dense parenchyma or dense breasts.  High resolution US can also 
be used to detect occult cancers or be useful with patients with dense breasts.  However, 
there is limited detection of DCIS and microcalcifications.  Additionally, a negative US 
never supersedes the results of a MG, and negative US result does not indicate the lack 
of a tumor.   
Studies have shown that US detects 2.7-4.6 cancers per 1000 asymptomatic 
women who have dense breast or negative MG findings.  Yet, the use of US imaging 
leads to a high false positive rate and a low positive predictive value (PPV) of 8.8%-11%.12 
A 2002 study looking at 27,825 patient examinations (11,130 asymptomatic 
women) found 246 cancers in 221 women.  The addition of US screening allowed for the 
detection of smaller and lower stages of cancer than physical examination (PE) and 
increase detection in occult cancer.  The sensitivities for the study were 77.6%, 27%, and 
75.3% for MG, PE, and US, respectively.  Sensitivity of US was more or less unaffected 
by breast density or age.  From the women with non-palpable invasive cancer, 42% of 
cancers were detected with US only.  From the subgroup of US only detected cancer 70% 
were <1 cm and 89% were node negative, which would give the best prognosis and the 
largest number of options for treatment.  However, the authors mention that the benefits 
of the screening must be weighed against the false positive (FP) rate of 2.4%.  Also rate 
of positive biopsy due to US detection is much lower than in MG.16 
Another study done in Germany in 2012 suggests that there is little or marginal 
benefit to US screening.  They were able to detect additional cancers that MG did not, but 
the PPV for the study was 0.21%.18 
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 Therefore, US seems has some benefits as a screening tool, but at the risk of 
additional FPs and unnecessary biopsies.  Additionally, US is highly operator 
dependent.12, 16  However, US has been useful as a follow-up imaging modality for 
patients with dense breasts or at high risk. 
1.4.3 Magnetic Resonance Imaging 
 MRI has been used for staging and treatment planning and has shown to be helpful 
at screening high risk patients.12, 13, 19  As seen in Table 1.2, there are different 
recommendations for screening depending on the cancer risk of the patient.  Women who 
are at high risk are encouraged to get annual MG and MRI imaging done.  Annual MRI 
screening can start as early as age 30.  High-risk patients usually are carriers of 
deleterious BRCA genes, have first-degree relatives with BRCA mutation, or received 
chest irradiation between 10-30 years of age. 12, 13  High-risk women tend to have an 
earlier onset of cancer and therefore, may benefit from earlier screening using MRI, since 
MG would have lower sensitivity in patients under the age of 40.  MRI is usually not 
recommended for average risk patients even if they have dense breasts.12 
MRI shows higher sensitive of over 90%. Yet, there is still a low specificity of 40%-
80%.  Sensitivity tends to be greater in invasive carcinomas compared to DCIS.  When 
combined with MG there is a 58% increase in sensitivity and a 44% increase when 
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Table 1. 2 Recommended screening for patients depending on risk of cancer.13   
  
  
Overall, MRI can detect cancers that are not visible via other modalities due to its 
higher sensitivity, especially DCIS and ILC. Although MRI can be used for screening high 
risk patients, it has also been utilized for staging and treatment planning for new 
diagnosed patients.  However, preoperative or perioperative MRI may not be beneficial 
for patient care since it can lead to a higher false positive rate, delay in treatment, higher 
costs.  Also, there is no significant effect on the long-term survival of the patients due to 
MRI results compared to standard imaging methods.  Additionally, there is evidence in 
the literature to suggest that perioperative MRI has led to an increase in mastectomies.19 
1.4.4 Positron Emission Tomography 
 PET is a non-invasive exploratory technique for breast imaging, which uses 
radioactive tracers such as fluorodeoxyglucose (FDG) to obtain information about the 
uptake and metabolism of glucose.  Malignant tissue tends to have both a higher uptake 




Women with <15% lifetime risk for 
breast cancer 
Annual MG starting at age 40 
High risk 
BRCA1 or BRCA2 carriers, untested first 
degree relatives of BRCA mutation 
carriers 
Annual MG and MRI starting by age 30 
but not before age 25 
Women with >20% lifetime risk for 
breast cancer on the basis of family 
history 
Annual MG and MRI starting by age 30 
but not before the age 25, or 10 years 
before the age of the youngest affected 
relative, whichever is later. 
History of chest irradiation received 
between the ages of 10 and 30 
Annual MG and MRI starting 8 years 
after treatment; MG is not recommended 
before age 25. 
Intermediated risk 
Personal history of breast cancer, 
ovarian cancer, or biopsy diagnosis of 
lobular neoplasia or atypical ductal 
hyperplasia 
Annual MG from time of diagnosis; either 
annual MRI or US can also be 
considered 
Women with dense breasts as the only 
risk factor 
The addition of US to screening MG may 
be useful for incremental cancer 
detection. 
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tumors FDG-PET, the review article reports a range of 48-95.7%.  However, sensitivity 
reduces when the tumor is sub-centimeter due to a decrease uptake in FDG. FDG-PET 
seems to be a more reliable modality compared to conventional techniques (MG, US, 
etc.), but does not out preform magnetic resonance mammography and MRI when 
diagnosing primary tumors.  Yet, FDG-PET can only be recommended for the detection 
of metastases and recurrent disease.  Compared to conventional imaging, FDG-PET 
shows increased efficacy and similar sensitivity, but with lower false positives.20 
1.4.5 Experimental Imaging Modalities  
There are additional imaging modalities that are still within the experimental stages 
and have not been widely used in a clinical setting yet, according to Vreugdenburg, et. al.   
A few of these imaging modalities include digital infrared thermal imaging (DITI), electrical 
impedance scanning (EIS), and elastography, which include electronic palpation imaging 
(EPI) and ultrasound elastography (USE). 
 DITI produces a heat map or thermogram of the breast and is captured using 
infrared cameras.  Usually, DITI has a very low sensitivity, but with development of high 
resolution infrared cameras the topic has been revisited.  Tumors can be detected by DITI 
due to localized increase in skin temperature, since tumor display increased vascularity, 
vasodilation, and recruitment of inflammatory cells. 
 Cancer cells have increased electrical conductivity and lower impedance 
compared to healthy cells.  Therefore, EIS has also been utilized to locate breast tumors. 
 EPI creates pressure maps of the breast where the tumor is a more rigid structure 
compared to healthy tissue.  USE compares the strain between healthy and cancerous 
tissue. 
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 However, for this review article, the authors mention that a few studies have been 
done on asymptomatic patients and therefore they do not recommend including these 
particular imaging modalities as screening tools for the time being.20 
 
Table 1.3 Summary of the sensitivity and specificity of DITI, EIS, and USE from literary 
search. 20 
Modality Sensitivity (Median) Specificity (Median) 
DITI 25.0-96.7% (82%) 11.8-84.9% (55%) 
EIS 62.0-97.5% (83%) 42.0-80.9% (68%) 
USE 35.4-100% (84%) 21.1-98.9% (88%) 
 
 
1.4.6 Problems with Current Imaging Modalities for Breast Cancer  
 Despite the multiple imaging modalities available and years of screening studies 
done in the field of breast cancer detection, there is still room for improvement.  The 
overall goals are to reduce the rate of late-stage disease, decrease cancer mortality, and 
detect aggressive tumors early. As mentioned previously, MG tends to lead to FPs, which 
leads to the problem of overdiagnosis.  Overdiagnosis is the detection of cancer that if 
left untreated would not be clinically significant or detrimental.  As a result, overdiagnosis 
can then lead to overtreatment. 14, 21   
 In a Canadian study involving 89,835 women being screened for breast cancer, 
there was one over-diagnosed breast cancer for every 424 patient who received MG 
imaging.  Additionally they found that annual MG for women 40-59 did not reduce the 
mortality rate.  As seen in Figure 1.4, there is very little difference between the survival 
probability between the group of women that received MG screening and the control 
group that did not receive imaging. 15 The results found in this study seem contrary to 
what has been reported in the literature previously.  Nevertheless, the report has sparked 
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media attention in the United States, and has women asking if MG is necessary or 
worthwhile. 
 
Figure 1.4 Breast cancer specific mortality from cancers diagnosed in screening period, 
by assignment to mammography or control arms.15 
 
Survival rates for breast cancer have improved over the past few decades.  
However, the reason behind this trend can be debated.  The decrease in mortality rate 
may be due mostly to the development of adjuvant therapies and better treatment plans 
for patients and not so much the early detection of cancer.  Therefore, there is a need for 
early detection of aggressive tumors before it progresses or form metastases.  However, 
there is the issue of the preconceived notion among doctors and patients of not doing 
enough for a patient even if the cancer is indolent.21   Additionally, there is a need for 
imaging technology that can differentiate between benign and malignant tumors.   
 
1.5 Optical Imaging 
Since there are areas of breast cancer imaging that need improvement, OI imaging 
methods, such as diffuse optical tomography (DOT), have emerged as a novel imaging 
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modality for this setting.  DOT uses optical transmission measurements with non-ionizing, 
low-intensity, near-infrared light to generate three-dimensional maps of various tissue 
parameters. Optical property contrast from endogenous chromophores [oxyhemoglobin 
(HbO2), deoxyhemoglobin (Hb), water, and lipid] can distinguish malignant from normal 
tissue.22-25 For example, it has been reported that total hemoglobin (HbT) levels, which 
relate to tumor blood vessel density, are double those in benign breast lesions26; and 
vascular changes precede measurable structural changes in mouse models.27  
DOT works on the principles that govern light interaction in biological tissue.  
Different types of optical imaging systems can be employed to capture this light 
interaction.  Afterwards, light propagation models and optimization algorithms can be 
utilized to reconstruct the optical properties and chromophore concentration in the tissue. 
1.5.1 Light and Tissue Interactions 
 Biological tissue is optically strongly scattering and tends to be weakly absorbing 
especially within the 400-1350 nm spectral region.  Absorption and scattering are light 
phenomena that occur when light is shined through a medium.  Absorption refers to a 
decrease in intensity of light as it travels a certain path distance (x) as shown by equation 
1.1. 
𝐼(𝑥) = 𝐼0𝑒
−𝜇𝑎𝑥      (1.1) 
I(x) is the intensity of light after it has travelled distance x.  I0 is the initial intensity of light 
and μa is the absorption coefficient.  Major causes of absorption in biological tissue come 
from hemoglobin, melanin, and water.28 Figure 1.5 shows oxy- and deoxy-hemoglobin 
absorption spectrum in the near-infrared range.  
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Figure 1.5 The molar extinction coefficients for oxyhemoglobin (HbO2) and deoxy-
hemoglobin (Hb) for light in the near infrared range.29 
 
Scattering is when light changes direction due to some obstacle or media of 
different optical properties.  The scattering coefficient μs is the probability that a photon 
will scatter per unit length.  Beer’s law describes the probability of transmittance (T) 
through distance x (Equation 1.2). 
𝑇(𝑥) =  𝑒−𝜇𝑠𝑥      (1.2) 
Scattering in biological tissue usually occurs when light interacts with structures such as 
nuclei.28 
1.5.2 Optical Imaging Systems 
After understanding light interaction in biological tissue, optical systems can be 
developed to capture this phenomenon. There are three types of optical systems: time 
domain (TD), frequency domain (FD), and continuous wave (CW).  Table 1.4 shows a 
summary of the different optical systems. 
 
   19 
 
Table 1.4 Summary of types optical systems.28 
Type of Imaging 
System 




Impulse Photon counter 
Information-rich but slow 







phase of emitted 
light 
Faster and less 








TD systems work by sending short light pulses through a medium and detecting 
the light as a function of time using a photon counter.28, 30, 31 The resulting signal has a 
lower peak amplitude and has a broader curve than the input signal.  The peak of the 
detected signal yields information about the path length of the light.  A highly scattering 
medium would have a later peak due to the longer path length.  The decreasing slope of 
the signal gives information about the absorption of the medium.  A sharper slope would 
mean higher absorption.30 
 FD systems use lasers that modulate light in the 100-1000 MHz range.  The system 
detects the amplitude and the phase shift of the signal, which can be used to determine 
absorption and scatter.  The same information as TD systems is acquired, but FD systems 
cost much less.28, 30, 31 
 Last, CW systems use unmodulated or low modulated (<10 kHz) light that detects 
only the amplitude of the signal.  Some of the advantages are that these systems are low 
cost and can be used for dynamic imaging.28, 30, 31  However, it is difficult to distinguish 
absorption from scattering effects by using this approach.31 
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Table 1.5 shows a summary of clinical optical imagers from several optical imaging 
groups that are investigating breast cancer in the clinical setting.  As for the groups led 
by Boas, Zhu, and Pogue, they combine traditional imaging modalities with optical 
imaging (MG, US, and MRI).32-34  Tromberg’s system is a DOS system that has one 
source and one detector.  The DOS system is used to create line scans of the tumor 
region, which can be used to create 2D surface maps of optical parameters.35  Last, 
Yodh’s group does DOT imaging with a parallel plate design and is capable of creating 
3D tomographic images.36 
1.5.3 Iterative Image Reconstruction Algorithm 
 
 
Figure 1.6 Flow diagram of the optimization algorithm for the inverse problem.30 
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After the data has been collected the images are reconstructed. The first 
component of the image reconstruction algorithm is the initial guess, which is an estimate 
of the spatial parameters of μa and μs (see Figure 1.6).  The forward model is run to predict 
how light will travel through the medium with the parameters from the initial guess.  From 
there the prediction model is compared to the experimental data and the error between 
these two measurements is found.  If the error is not below a certain threshold the optical 
parameters are changed and updated and the forward model run again.  The updating 
phase of the algorithm takes place until the predicted model and experimental 
measurements are less than a designated threshold in which the final image is 
presented.30 
1.5.4 Light Propagation Models 
 In order to run the iterative scheme, there needs to be a forward model in place.  
The forward model is the light propagation model that predicts how light will travel through 
a medium of certain optical properties.  The most basic form of light propagation through 





=  −?̂? ∙ ∇Φ(𝑟, ?̂?, 𝑡) − 𝜇𝑡Φ(𝑟, ?̂?, 𝑡) + 𝜇𝑠 ∫ Φ(𝑟, ?̂?, 𝑡)𝑝(?̂?′ ∙ ?̂?)𝑑Ω
′
4𝜋
+ 𝑆(𝑟, ?̂?, 𝑡) (1.3) 
The spectral radiance, Φ, is the energy rate per area per solid angle (W m-2 sr-1).  
The spectral radiance is terms of position (r), the unit direction vector (s), and time (t).  
The source term is denoted by S and μt is the summation of μa and μs’.  The function S is 
the spectral radiance of the source. The function, p, is the probability that light will 
probability of photons scattering from ?̂?𝑖𝑛 to ?̂?𝑜𝑢𝑡 and is defined by the Henyey-Greenstein 
phase function: 





    (1.4) 
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where g is anisotropy. Anisotropy can range from -1 to 1 with a value of zero would 
indicate isotropy. For most biological tissue g=0.9, which indicates that the medium is 
highly forward scattering. 
However, for light modelling in biological tissue such as breast tissue the diffusion 
approximation is used since the medium is highly scattering.  The diffusion approximation 
is derived from the RTE.  To obtain the diffusion approximation there are a two of 
assumptions made: 
1. The medium is nearly isotropic  
2. μa << μs. 
 






+ μa𝐼(𝑟, 𝑡) − ∇ ∙ [𝐷∇𝐼(𝑟, 𝑡)] = 𝑆(𝑟, 𝑡)   (1.5) 
If we are concerned with steady state where 
𝛿𝐼(𝑟,𝑡)
𝛿𝑡
= 0 then the diffusion approximation 
is: 
μa𝐼(𝑟, 𝑡) − ∇ ∙ [𝐷∇𝐼(𝑟, 𝑡)] = 𝑞(𝑟, 𝑡)    (1.6) 
where I is the intensity (W m-2) and can also be defined as: 
𝐼(𝑟, 𝑡) =  ∫ Φ(𝑟, ?̂?, 𝑡)
4𝜋
𝑑Ω         (1.7) 
Since I has no dependency on angle, the light is isotropic.  The source term expressed 





      (1.8) 
 In a discretized space, each unit (voxel) has designated optical properties (μa, μs’) 
for each wavelength being observed.  When the reconstruction algorithm updates, it is 
updating the optical properties of each unit to closer mimic the optical properties from the 
imaged volume.  After the updating the optical properties, this information is used again 
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to determine how the light travels through the medium and what the intensity will be on 
the surface of the medium where the measurements take place.  Therefore, optical 
properties such as μa, μs, and D are vectors that denote value for each voxel.  Essentially, 
the reconstruction will develop a three-dimensional map of the optical properties. 
1.5.5 Chromophore Concentration 
After the optical properties are determined using the reconstruction algorithm, the 
concentration of a chromophore can be found using Beer-Lamberts Law, which is defined 
as: 
𝜇𝑎(𝜆) =  ∑ 𝜀𝑖
𝜆𝐶𝑖
𝑁
𝑖=1      (1.9) 
where λ is the wavelength being employed, ε is the extinction coefficient, and C denotes 
the concentration.28    
 
1.6 DOT Breast Imaging 
DOT uses optical transmission measurements with non-ionizing, low-intensity 
near-infrared light to generate three-dimensional maps of various tissue parameters. 
Optical property contrast from endogenous chromophores can distinguish malignant from 
normal tissue25, 37-39.  For example, it has been reported that total hemoglobin (HbT) 
levels, which relate to tumor blood vessel density, are double those in benign breast 
lesions26; and vascular changes precede measurable structural changes in mouse 
models.27 
In a systematic review, Leff et. al. looked at several studies that involved 2,000 
women in total and found that about 85% of tumors were detectable by using optical 
techniques.  They determined that hemoglobin concentration and oxygen saturation were 
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the two important factors for determining breast disease.  Combining the studies they 
found that the average [HbT] for malignant disease was 65±35 μmol/l and SO2% was 
66±24%.  For fibroadenomas the average was 54±13 μmol/l and 69 ± 3% for [HbT] and 
SO2%, respectively.  In healthy tissue, [HbT] was 21 ± 6 μmol/l and SO2% was 68 ± 5.31  
The [HbT] for malignant disease were much higher than healthy tissue, while SO2% had 
similar levels.  However, there are still some difficulties at distinguishing between 
malignant and benign tumors.  The best results for tumor differentiation seem to be with 
FD systems with US or MRI components.31 
 
Figure 1.7 Statistical analysis of the differences in Δ[Hb]% between healthy (n = 6), 
benign (n = 8), and tumor-bearing (n =14) breasts 15 seconds after the end of a breath-
hold. (a) Mean value and standard deviations of the average Δ[Hb]% in a 1-cm-sphere 
around the point of peak hemoglobin change. 40 
 
In a previous study, our group at Columbia University used dynamic diffuse optical 
tomography (DOT) imaging to observe the hemodynamics of different tumors to 
determine if a subject had a benign or malignant tumor, or was healthy.  The contrast 
mechanism that was used for the pilot and current study was a simple breath hold.  When 
a subject holds their breath there is an increase in intrathoracic pressure, which 
decreases the venous return of blood to the heart. Hence, there is an increase in blood 
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volume in the breast and when the subject breathes normally the blood volume returns to 
normal.   The quantified hemodynamic time traces showed variation between the healthy 
and tumor bearing breasts of a subject compared to that of a healthy subject who showed 
similar traces for both breast.  Additionally, there were slower recovery times for the 
tumor-bearing breast and higher Δ[Hb]% at the 15 second post breath hold image as 
seen in Figure 1.7 40 
 
1.7 Monitoring Neoadjuvant Chemotherapy 
1.7.1Monitoring NACT using Traditional Imaging 
NACT is widely applied as standard treatment for patients with newly diagnosed 
operable invasive BC.41   The goal of NACT is shrink the breast tumor as much as possible 
before surgical intervention. In this way an inoperable cancer may become operable, or 
an operable cancer can be converted from mastectomy to breast conserving therapy.  
Ideally a pathological complete response (pCR), meaning the complete disappearance of 
the tumor before surgery, is achieved. Studies have shown that patients with a pCR have 
a 90-95% five-year survival rate, while five-year survival rates for patients with no pCR 
are typically below 80%.42 Depending upon the exact definition, pCR is achieved in only 
15-40% of women. Recent studies have shown that changing therapy in patients that do 
not show an early response may benefit from a change in treatment regimen.43-47 
Therefore, it would be highly desirable to reliably determine who will and will not respond 
to NACT early in the treatment.3, 48 
Most NACT monitoring studies have concentrated on baseline and pre-surgical 
imaging to observe any residual cancer and estimate the size of the remaining tumor.  
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This is more or less for surgical planning purposes to assist physicians on whether breast 
conserving surgery is the best option or preform a full mastectomy.  The goal is to predict 
which patients received a pathological complete response and prevent surgery all 
together.  However, none of the traditional methods, such as clinical exam (CE), MG, and 
US seem to be accurate enough to estimate the pathological response or size of the 
residual tumor.2, 49-54  Some imaging studies have shown that MRI is more accurate than 
other imaging methods50, 51, yet other studies have seen little difference or have not been 
able to reliable predict response.2, 53  A meta-analysis of forty-four studies with 2050 
patients showed the MRI had a higher accuracy than CE or MG, but no difference 
between MRI and US.  The median sensitivity from the meta-analysis for MRI was 92% 
and the median specificity was 60%.54 
 Croshaw et. al. combined retrospective data with 6 other studies to determine the 
efficacy of CE, MG, US, and MRI, as seen in Table 1.6.  US has the best sensitivity of all 
the imaging modalities, but consequently the lowest specificity, which was the result of 
the highest number of false positives.  CE had the lowest sensitivity at 50% but the highest 
specificity of 82%.  Last, MRI showed the highest accuracy when determining pCR.53  
Table 1.6 Results of Data Synthesis to Predict Tumor Response.53 
 CE Digital MG US MRI 
Total Patients 259 255 301 230 
Sensitivity 50% 81% 90% 86% 
Specificity 82% 48% 33% 79% 
Accuracy 57% 74% 79% 84% 
 
One study did imaging at the mid-treatment time point to see if tumor response to 
NACT could be predicted before surgery.  When predicting the response of the tumor at 
the mid-time point the accuracy of CE, MG, US, and MRI was 58%, 56%, 63%, and 67%, 
respectively.51  Not only do none of these methods seem better than the others including 
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CE, but also none of these methods have a high enough accuracy to be clinically useful 
in predicting response at the mid-time point. 
1.7.2 Optical Tomographic Imaging for Neoadjuvant Chemotherapy 
 Although there have been several tumor diagnosis OI and DOT studies25, 26, 36, 55, 
56 including our own23 that show promising results, the technology has found a niche in 
NACT monitoring.3   Since traditional method lack the accuracy or the feasibility for 
treatment monitoring or predicting response, DOT has emerged as a promising novel 
imaging modality for this important application 
There are several advantages to using optical imaging (OI) to monitor breast tumor 
response over conventional imaging techniques.  For example, OI using non-ionizing light 
sources that allow for multiple imaging session within a short period of time.  Therefore, 
measurements can be taken a few weeks to a few days apart from each other with no 
adverse effect.  OI is also sensitive to parameters that change over the course of 
treatment, such as tissue vascularity or hypoxia.3, 48  Several studies have shown that 
there is a change in optical properties over time during the course of neoadjuvant 
chemotherapy. 48, 57-60  The purpose of these monitoring studies is to determine early 
within the treatment whether the patient will respond to the therapy or not.  Therefore, 
more personalized treatments could be developed to optimize the patient outcome of 
those who do not respond. 3, 48   
 Some studies have demonstrated that there is a decrease in total hemoglobin 
concentrations ([HbT]) time for subjects that had received a pathological complete 
response (pCR) or near-pCR.57, 58   Another study using spectroscopic methods examined 
34 women and found significant difference mid-treatment time point between pCR and 
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non-pCR subjects where the pCR subjects had a larger decrease in normalized 
deoxyhemoglobin concentrations ([Hb]).59  Additionally, the same group was able to 
predict tumor response to NACT using the baseline measurements and determined that 
oxygen saturation was higher in patients that were going to receive a pCR.60 
Since optical imaging has been shown to predict tumor response we performed a 
clinical study monitoring tumor response using our dynamic optical imaging system.   
 
1.8 Overview of this Thesis 
 This work aimed to employ an existing dynamic diffuse optical imaging system to 
image breast cancer patients undergoing NACT.  For the study, two different types of 
data were collected: static data (single 3D image) and dynamic data (3D movies).  The 
goal was to find imaging biomarkers that could be used to accurately predict treatment 
response of the patient as early as two weeks after treatment initiation. Currently 
physicians need to wait until the 5 months of NACT has been completed and the patient 
had undergone surgery, to find out if a patient had a good response to treatment. If not, 
it is often too late to start a new therapy. With non-invasive, non-ionizing DOT imaging 
we may be able to determine within weeks of treatment if the tumor will disappear in 5 
months; giving the physician and patient new options in therapy before expensive drugs 
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Chapter 2: Study Design                     | 
2.1 Introduction 
Neoadjuvant chemotherapy (NACT) is widely applied as standard treatment for 
patients with newly diagnosed operable invasive BC.41   The goal of NACT is to shrink 
the size of the breast tumor as much as possible before surgical intervention. In this way 
an inoperable tumor may become operable, or breast conserving surgery can be 
performed instead of a mastectomy.  The best outcome would be a pathological complete 
response (pCR), in which there is no residual cancer after treatment. Studies have shown 
that patients with a pCR have a 90-95% five-year survival rate, while five-year survival 
rates for patients with no pCR are typically below 80%.42 Depending upon the exact 
definition, pCR is achieved in only 15-40% of women. Recent studies have shown that 
changing therapy in patients that do not show an early response may benefit from a 
change in treatment regimen.43-47 Therefore, it would be highly desirable to reliably 
determine early in the treatment, who will and will not respond to NACT.3, 48  
Our NACT monitoring study consists of imaging 40 women at six different time points 
during their treatment.  We have hypothesized that DOT imaging can determine early 
within treatment whether the patient will or will not have a pathological response to the 
chemotherapy.  For this chapter, we provide the methods and overview of the clinical pilot 
study. 
 
2.2 Clinical Study Overview 
2.2.1 Patient Recruitment and Treatment 
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The study was approved by The Columbia University Institutional Review Board 
and is HIPPA compliant.  Written consent was obtained by each subject.  Women over 
the age of 18 who were diagnosed with stage II or stage III breast cancer and were to 
undergo NACT were eligible for the study.  The primary tumor had to be at least 1 cm in 
diameter and women with metastases were not eligible. Each patient receives twelve 
weekly treatments of Paclitaxel followed by four cycles of doxorubicin and 
cyclophosphamide (AC) given every other week.  There are six DOT imaging time points: 
baseline, cycle 3 and 5 of Paclitaxel, before AC, cycle 1 and 2 of AC, and before surgery 
(Fig 2.1).  
 
Figure 2.1 Timeline for subject treatment and imaging. 
 
These imaging time points were chosen for two reasons.  First, we wanted to study 
tumor progression as a patient received chemotherapy throughout the entire course of 
treatment.  Second, we wanted to observe if there are time points during chemotherapy 
that can be used to predict the overall pathological response of the subject.   Imaging time 
points were selected close to the beginning of treatment and at points when the 
chemotherapy agents were changed.  This was designed so that we could observe the 
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beginning of each treatment to analyze early effects.  Response to treatment was based 
on histology performed after surgery. 
2.2.2 Baseline Biomarker 
 Before the beginning of treatment, diagnostic biopsies for each patient were tested 
for specific biomarkers that may assist in determining optimal treatment.   Current clinical 
care for breast cancer patients include determining biomarkers, such as estrogen 
receptor (ER), progesterone receptors (PR), and amplification of HER-2/neu (HER2),as 
well as, a widely used test of Ki67 staining. 
ER and PR are hormone receptors and are used to predict the response to anti-
estrogen therapy.61  Specifically, ER-α, an isoform of ER, is responsible for mammary 
gland development and tumorigenesis.62  Positive ER and PR statuses have a fairly good 
clinical prognosis, while negative ER and PR status have a poor prognosis. HER2 is an 
oncogene, which is linked to negative ER/PR status.  HER2 is also part of the standard 
work-up on newly diagnosed patients.  Amplification of HER2 is associated with a poor 
prognosis.61  Another biomarker we observe for this study is Ki67, which is a measure of 
cell proliferation in the cancer.  This is a widely used biomarker that has been used to 
predict response to chemotherapy. 61 
There has been sufficient evidence to support that the pathologic response 
predicts improved clinical outcome in specific BC subtypes, such as triple negative BCs 
(negative for ER, PR, and HER2).63  Therefore, combining these biomarkers with optical 
imaging features may increase the accuracy of our prediction models to help determine 
the pathological response to treatment before surgery. 
2.2.3 Clinical Exam Measurements 
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 Before each cycle of chemotherapy, patients would receive clinical exams and 
have their tumors measured extrinsically, by use of calibers.  The maximum dimension of 
the tumor was used for analysis.  The clinical measurements were taken to give the 
physicians an indication of how well the patient was doing without using any imaging or 
biopsy techniques.  We used this information to compare to our DOT measurements to 
conclude if DOT can perform better than these standardized clinical measurements. 
2.2.4 Residual Cancer Burden 
At the end of the treatment breast cancer surgery was performed and any 
remaining tumor mass was removed and evaluated by histopathology. For each person 
the residual cancer burden (RCB) score was calculated. The RCB score takes into 
account the size and proportion of the residual primary tumor and number and diameter 
of residual lymph nodes.63   
The following formula is used to calculate the RCB score: 
𝑅𝐶𝐵 = 1.4(𝑓𝑖𝑛𝑣𝑑𝑝𝑟𝑖𝑚)
0.17
+ [4(1 − 0.75𝐿𝑁)𝑑𝑚𝑒𝑡]
0.17  (2.1) 
where finv is the proportion of the primary tumor bed that contains invasive 
carcinoma, LN is the number of axillary lymph nodes that contain cancer, d are the 
dimensional measurements of the primary (dprim) or metastatic cancer in the lymph node 
(dmet).  The primary tumor dimension was determined by using the two largest dimension 
and calculating: 𝑑𝑝𝑟𝑖𝑚 =  √𝑑1𝑑2. 
The RCB score is a score given on a continuous scale, but then can be further 
binned into classes.  A person was considered a pathologically complete responder (pCR) 
if the RCB ≤ 0.5 (RCB-0). A patient with RCB > 3.28 (RCB-III) was considered a non-
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responder. For values in between patients were classified as partial responders (RCB-I 
for 0.5< RCB≤1.36, and RCB-II for 1.36< RCB≤3.28).64 
Both pCR and RCB have been identified as surrogate endpoints for clinical 
outcome, as pathologic response (i.e. pCR or low RCB) associate with a favorable 
prognosis including longer disease free survival and overall survival.24, 63-65 Yet, 
pathologic response rates are low.  In a pooled analysis of over 6,000 patients 
administered neoadjuvant anthracycline-taxanes, pCR was achieved in only 15% in all 
BC subtypes. “Responders” as determined by a RCB score of 0 or 1, occur in 
approximately 40% of patients with BC after NACT, with “non-responders” (RCB = 2 or 
3) identified in about 60%.  RCB independently predicts for distant BC relapse-free-
survival in multivariate models that include pCR.64  Recent NACT guidelines recommend 
routinely checking RCB.65   
For the NACT monitoring study, we used the RCB score and RCB class as an 
endpoint to compare with our DOT features.  Our goal was to correlate the RCB score 
with our DOT features and to also predict pCR. 
 
2.3 Overview of DOT Imaging 
2.3.1 Instrumentation and Patient Interface 
To image subjects we used a custom built digital dynamic DOT system.  Our current 
breast DOT system is a continuous wave dynamic imaging system that emits four 
wavelengths.  Two of the wavelengths (765 and 808 nm) are modulated at 5 kHz, and the 
other wavelengths (827 and 905 nm) are modulated at 7 kHz.  Modulated light sources 
were used to implement a lock-in detection system to reduce noise.22, 66 
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Due to the large geometries that are being imaged, the signals received by the 
detection unit vary greatly.  To combat this problem, the imaging system was designed to 
have a large dynamic range (~120 dB).  Each source detector pair is allocated a gain 
setting that gives the acquired signal the optimal signal to noise ratio (SNR) without 
saturation.  The gain settings determine how much amplification is necessary for the 
signal from each source-detector pair. 
Table 2.1 Summary of DOT breast imager parameters.22 
 
Parameter Value 
Sources 32 per breast, 64 total 
Detectors 64 per breast, 128 total 
Wavelengths 
~5 mW at 765 nm, 
 808 nm,827 nm, 905 nm 
Temporal Response 1.7 Hz – 111 Hz 
Dynamic Range ~ 108 (158 dB) 
System Size 104 cm x 79 cm x 66 cm 
Power Consumption 3.5 Amps @ 120 V AC 
 
There are a total of 64 sources and 128 detectors (see Table 2.1).  The patient interface 
is comprised of two sets of four concentric rings that hold the source and detector fibers 
in place, and can be adjusted to accommodate different breast sizes.  Each set of the 
rings holds a total of 64 fibers in which all fibers are detectors, but half are collocated 
sources.  Fibers are placed in a source-detector-source-detector pattern around each 
ring.  There are four rings that vary in size with a diameter of 4, 8, 12, and 16 cm and hold 
8, 12, 16, and 28 fibers, respectively.  The angle between the fibers also changes as the 
size of the rings increase (60˚, 45˚, 30˚, 15˚) to assure fibers are normal to the tissue and 
maximum coverage of the breast is assured.  Larger rings can be removed to 
accommodate smaller breast sizes. However, frame rate is dependent on the number of 
sources and detectors used to image, so if a ring is removed the system images at a 
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faster frame rate.  We preform 3D imaging of both breasts simultaneously with a frame 
rate of 1.7 Hz when all sources and detectors are used.22   The fast acquisition time allows 
us to view hemodynamic changes that occur due to stimuli such as a breath hold (~30 
sec). 
 
Figure 2.2 Image of the DOT breast imager with translating ring interface. 
 Our DOT system is capable of dynamic imaging of both breast simultaneously, 
which allows us to compare the healthy and tumor bearing breasts. There is no 
compression or extrinsic contrast agents necessary, which allows for more comfortable 
imaging experience for the patient.  Also, the system has a fairly quick acquisition time 
which allows us to acquire about 1000 frames within 8-10 minutes. 
2.3.2 Patient Imaging 
The height of each ring was adjusted for each subject to assure that all of the 
optical fibers made contact with the tissue.  The subject placed her breasts inside the 
translating rings and the gain settings were automatically determined for each source-
detector pair through custom software written in LabView.  The gain settings determine 
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how much amplification is necessary for the signal from each source-detector pair.  After 
optimizing the gain settings for the subject, imaging began with a baseline measurement 
of about 2 minutes in which the patient remained stationary.  Next, the patient was 
instructed to hold their breath for thirty seconds, and then was given about 90 seconds of 
recovery time.  Each patient performed two to three breath holds, and the total imaging 
time was around 8 minutes (Figure 4).  Once the subject imaging was done and she was 
removed from the imaging probe, a reference solution was imaged for about a minute.  
The reference solution was composed of 20 % Intralipid and 1% India ink, which was 
diluted to have similar optical properties as breast tissue. 
 
 
Figure 2.3 Timeline for subject imaging and an example of how data is selected to 
reconstruct images.  Baseline refers to the period of time that the subject remains 
stationary.  Subjects perform three breath holds (BH) for about 30 seconds and given 90 
seconds to recover.  Reference solution is imaged for one minute after the subject 
imaging is over. 
 
The acquired data was reconstructed to create both static and dynamic images.  
Static images were reconstructed from the measurements acquired during the subject’s 
baseline imaging and the reference solution imaging.  By using a reference solution of 
known optical properties, static 3D images of oxy-hemoglobin concentration, deoxy-
hemoglobin concentration, and water fraction were made.  To create the dynamic images, 
one of the breath holds was selected for reconstruction.  The baseline measurement for 
the dynamic images were taken 30 seconds before the patient began holding their breath 
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and was used to calculate percent change of oxy-hemoglobin and deoxy-hemoglobin 
concentrations for the duration of the breath hold, as well as, 30 seconds of the recovery 
time. About one dynamic image per second was reconstructed so that the hemodynamic 
effect of the subject’s breath hold could be analyzed.  
Other studies have used the Valsalva maneuver, mechanical compression, or 
contrast agent, such as ICG to observe hemodynamic effects of breast tumors67, 68.  
However, these pose a couple of challenges.  One group needed to exclude a third of 
their subject population due to motion artifact caused by the Valsalva maneuver68.  This 
maneuver requires to breathe out for a certain length of time which could cause motion 
issues during imaging.  However, with the breath hold, the subject is not constantly 
moving during the imaging.  Additionally, there is no extrinsic contrast agent that could 
cause some discomfort to the patient. 
2.3.3 Mesh Construction  
 
Figure 2.4 Computer rendering of translating ring interface.  The location of each source 
and detector is known, as well as, the distance between rings.  This information can be 
used directly to create 3-dimensional meshes for reconstructions. 
 
Meshes for image reconstructions were created using the geometry of the rings 
and known locations of each source and detector (Fig 2.4). Therefore, meshes were 
generated custom made for each individual subject, which improves the accuracy of the 
reconstructed image.  The meshes extend 2 cm past the largest ring to account for the 
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effects that the chest wall might have on the reconstruction.  Meshes contained 
approximately 60,000 to 70,000 elements.   
 Meshes are 3-dimensional volumes that are segmented into voxels.  Each of the 
voxels are an unknown to which the reconstruction algorithm assigned a value (i.e. μa, μs, 
etc.).  The meshes are also used to predict how light travels through the medium that has 
been assigned specific optical parameters.  Mesh generation is an essential step in 
reconstructing optical images, since the distance between the source and detector are 
one of the key factors for predicting how light travels through the medium.  Additionally, 
the meshes are used to compile the final 3D DOT image. 
2.3.4 Reconstructions 
 The imaging data was pre-processed and reconstructed to yield 3-dimensional 
images and movies of the whole breast.  A PDE-constrained multispectral imaging 
method that uses the diffusion approximation as a model for light propagation.69 Static 
and dynamic reconstructions were performed on previously developed codes within the 
lab.  More detail about the specifics of the reconstruction algorithms can be found in 
chapters 3 and 4.  Otherwise, optimization schemes similar to the reconstruction 
algorithm structure explained in Chapter 1 were utilized. 
 
2.4 Statistics 
2.4.1 Standard Statistics 
The mean and standard deviation were determined for each of the previously 
described features.  One way ANOVAs were performed for comparison of more than two 
groups.  Otherwise, two-way unpaired student t-tests between designated groups was 
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performed.  Linear regressions of the RCB score versus different DOT features in which 
the correlation coefficient and p-value were determined. 
2.4.2 Sensitivity Analysis 
Classifier performance can be determined with the help of a confusion matrix.  A 
confusion matrix displays how many of a given population was predicted correctly for a 
particular feature being observed (i.e. how many women were correctly diagnosed with 
breast cancer using x-ray mammography).  Figure 2.5 shows how the confusion matrix is 
constructed.   
 
Figure 2.5 A template for a confusion matrix.70 
Subjects are classified based on an experimental feature (hypothesized class), but 
are compared to a gold standard of diagnoses (True Class).  Using our previous example, 
a true positive would be a subject that had breast cancer and was classified as having 
breast cancer.  A true negative would be a subject that did not have breast cancer and 
was correctly classified as have no breast cancer.  A false positive (FP) or false negative 
(FN) were subjects that were not classified correctly.  The sensitivity and specificity of the 
confusion matrix are determined using: 









     (2.3) 
where TP and TN are the number of subjects that were true positive and true negative, 
respectively.  PD were the number of positively diagnosed subjects and ND were the 




     (2.4) 
Additionally the positive predictive value (PPV) and negative predictive value (NPV) can 








          (2.6) 
where PT is the number of subjects that were classified positive and NT were the number 
of subjects tested negative. 
 
Figure 2.6 Examples of ROC curves with the sensitivity and specificity at the Youden 
index.  An ideal ROC curve with an area under the curve (AUC) of 1 (A), a standard ROC 
curve with an AUC of 0.85, and a very poor ROC curve with an AUC of 0.56 (C). 
 
Receiver operating curves (ROC) compare the specificity and sensitivity of a 
diagnosis test and are efficient at determining the efficiency of classification techniques.  
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The sensitivity and specificity of several threshold values within a given feature are tested 
and the threshold that has the maximum value to the equation 1-(Sensitivity + Specificity) 
is considered the Youden index, which is the optimal cutoff point for the classifier.  The 
area under the curve of the ROC can be determined.  An AUC of 1 is ideal for a classifier 
(Fig 2.6A).  Examples of ROC can be seen in Figure 2.6 in which there are different AUCs 
and the location of the Youden index are identified with the corresponding sensitivity and 
specificity. 
Thus, the sensitivity, specificity, accuracy, positive predictive value (PPV), and 
negative predictive value (NPV) were determined from the Youden index of the ROC 
curve.  The sensitivity within this thesis denotes the percentage of the more responsive 
group that was diagnosed correctly.  Conversely, the specificity denotes the percentage 
of subjects in the least responsive group that were categorized correctly.   
Univariate and multivariate discriminant analysis with cross-validation was also 
employed and described in Chapter 7. 
2.5 Summary of Subject Population 
Table 2.2 Subject summary and pathologies. 
 Avg ± Stdev Range 
Age (Years) 49 ± 12 (29-73) 
BMI 29.8 ± 6.0 (18.3-44) 
Tumor Size (cm) 4.4 ± 2.7 (1.1-12) 
    
Menopausal State Pre-Menopausal Post-Menopausal 
Number of Subjects 20 16 
     
Cancer Type Invasive Ductal Invasive 
Lobular 
Mixed Ductal & 
Lobular  
Number of Subjects 32 4  1 
RCB Score RCB 0 RCB I RCB II RCB III 
Number of Subjects (Percent of 
subject population) 
14 (38.9%) 2 (5.5%) 14 (38.9%) 6 (16.7%) 
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There were forty women recruited and imaged for the study with four subjects 
being excluded due to drop outs or machine malfunctions.  Four patients were excluded. 
One patient completely stopped NACT after the first imaging. For 2 subjects, 
instrumentation failure during the imaging session resulted in corrupted data sets that 
could not be used. Finally, one subject opted to receive radiation therapy in addition to 
the traditional NACT therapy and therefore was removed from the analysis.  
Table 2.3 Number of subjects in each response category for each week. 
# of Subjects Baseline Week 2 Week 4 Week 0AC Week 2AC Pre-surgical 
RCB 0 14 13 12 10 11 7 
RCB I 2 2 2 2 2 2 
RCB II 14 13 14 13 12 11 
RCB III 6 6 6 6 6 6 
Total 36 34 34 31 31 26 
* Subject imaged during week 3 instead of week 2 (1 RCB 0 subject and 2 RCB II subjects) 
** Two subjects imaged at third AC cycle instead of the second cycle. 
   
As seen in Table 1, the average age of the women was 49 ± 12 in which the 
youngest woman was 29 and the oldest was 73.  The average body mass index (BMI) 
was 29.8 ± 6.0.  There were 20 pre-menopausal subjects and 16 post-menopausal 
women.  Most women had invasive ductal carcinoma (32 subjects).  There were four 
women with invasive lobular carcinoma and one subject with mixed ductal and lobular.  
In the discrete scale of RCB score, 14 subjects had an RCB of 0 (pCR), 2 subjects had 
an RCB of I, 14 subjects had an RCB score of II, and 6 subjects had an RCB of III.  Not 
all subjects were imaged at every time point.  Table 2 shows a summary of the number 
of subjects that were included in the analysis for each week for each response group. 
 
2.6 Novelty and Uniqueness of Current Study 
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The current study has several features that make it unique.  First, our imaging 
system solely operates as an optical system.  There have been studies of dual-imaging 
systems that combine near-infrared imaging with US, MG, and MRI.25, 26, 58, 71-75 The 
advantage is that commonly used imaging modalities that physicians are comfortable 
using are being used the combined information that near-infrared imaging has to offer.  
However, when it comes to treatment monitoring these imaging modalities lack the 
versatility or efficacy that is needed to image patients multiple times safely at a reasonable 
cost.  DOT uses non-ionizing light sources that allow for multiple imaging session within 
a short period of time.  Therefore, unlike x-ray imaging, frequent DOT measurements can 
be performed without adverse effect.  DOT is also sensitive to parameters that change 
over the course of treatment, such as tissue vascularity or hypoxia.3, 48   
There are several facets that make our current study unique to other imaging 
studies that have been published.26, 57, 59, 72-81  First, all subject receive the same 
chemotherapy regimen.  Other chemotherapy studies have subjects on different 
chemotherapy regimens, which could lead to different responses and thus make 
predicting the response to certain treatments difficult.  Second, we have six imaging time 
points spaced throughout the treatment with imaging concentrated towards the beginning 
of treatment and after switching chemotherapy agents.  We have recruited 40 subjects 
and analyzed 36 subjects, which is one of the larger optical studies performed to date. 
 Most importantly we are collecting both static and dynamic information which could 
lead to a more complete picture of what the tumor progression is under the treatment 
circumstances.  We can possibly use these two pieces of information to accurately 
monitor the tumor or possibly predict the response early within the treatment. 
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2.7 Conclusion 
 We have designed a study that allows for the collection and analysis of multiple 
facets of tumor progression throughout NACT.  Through the use of a versatile dynamic 
DOT imaging system, we have collected static and dynamic optical information.  For the 
remainder of this thesis, I present how this information was processed and analyzed, as 
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Chapter 3: Static Data Processing                            |  
3.1 Introduction 
Since DOT is sensitive to hemoglobin concentrations, it is capable of 
characterizing changes in vascular structures and blood perfusion in tissue.  Several 
studies have shown that there is a change in optical properties over time during the course 
of NACT. 26, 48, 57-60, 72-81 We have used a DOT breast imaging system previously 
developed in our group that is capable of acquiring 3D transmission data from both 
breasts simultaneously to measure spatially dependent concentrations of [HbO2], [Hb], 
[HbT], and water fraction (WF), and oxygen saturation (SO2%) on subjects receiving 
NACT.  We plan on looking at the percent change from the baseline of these parameters 
over time to track tumor progression and to correlate these changes with the pathological 
response of the subject.  
 
3.2 Challenges to overcome 
Since the DDOT system was set up for dynamic imaging, our previous studies had 
focused on the hemodynamics of breast cancer.  However, this has been the first study 
in which we planned to look at static imaging with the aid of a reference phantom.  
Therefore, several adjustments had to be made and techniques developed for the current 
data set to obtain accurate static images. 
The original code being utilized was a PDE-constrained multispectral imaging 
method that uses the diffusion approximation as a model for light propagation.   However, 
this code would work very well for some patients and pose huge problems for other 
patients.  There would be large artifacts, false positives in the contralateral breast, and 
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indeterminate cancer locations in our original protocol setup.  Also, the tumor-bearing 
masses would display blobs in the middle of the images which would be caused the by 
regularization within the reconstruction algorithm.  Regularization was kept constant for 
all patients but would have needed to be changed base on mesh size.  There is no method 
of determining this efficiently. 
Once we switched to the DCT reconstruction method, the artifacts at the surface 
of the images became clearer.  As a result, there needed some method of artifact removal 
incorporated into the pre-processing stage. We also added a method for determining the 
initial conditions for each reconstruction.  Last, there was no protocol put in place for the 




 Figure 3.1 shows an overview of the pre-processing protocol.  First, 30 seconds of 
the raw data are averaged for the patient and reference measurement and saved to text 
files.  There is no additional pre-processing methods performed on the raw data. 
 Next the forward model was run and the input and setup files were created.  The 







𝜆       (3.1) 
where 𝑀𝑡𝑎𝑟
𝜆  is the subject measurement for a specific wavelength, 𝑀𝑟𝑒𝑓
𝜆  is the reference 
measurement for a specific wavelength, 𝑃𝑟𝑒𝑓
𝜆  is the prediction measurement for a specific 
wavelength from the forward model, and 𝑧𝑡𝑎𝑟
𝜆  is the input value for the reconstruction.  The 
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setup files contain information for the reconstruction including the initial condition.  The 
evolutionary strategy was run and used to change the initial condition in the setup files.   
 
Figure 3.1 Overview of pre-processing steps to run static reconstructions. 
Also, the source-detector (SD) points are analyzed, the poor points are removed, 
and the input files are modify to reflect the changes.  Last, the reconstruction is run.  All 
the time points and the left and right breasts are pre-processed and run together.  This 
saves time and allows all the time point images to be processed the same way. 
3.3.2 Evolutionary Strategy 
Before utilizing evolution strategies for the static reconstructions all patients were 
given the same initial value for the reconstruction algorithm.  There has been evidence to 
support that the initial value can have a huge impact on the outcome of the inverse 
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problem.30  Additionally, the optical properties of breast tissue can vary drastically 
according to age or BMI.82  Therefore, there was a need for a more individualistic means 
of inputting the initial conditions into the reconstruction algorithms.  One simple solution 
was to use pre-written evolutionary strategy algorithms to determine an estimate of the 
breast tissue properties. 
 
 
Figure 3.2 Evolution Strategy uses an iterative process of recombination, mutation, and 
selection of a set of individuals Pk to determine optical properties. 
 
The initial guess for the full tomographic images is predetermined beforehand 
using evolutionary strategies.  Briefly, evolution strategies uses principles of nature such 
as survival of the fittest and heredity to determine the optimal solution for an ill-posed 
problem.  This is an iterative process that starts with a parent population of 
𝑃𝑘 =  (𝑥1, … ,  𝑥𝑛)𝑘 where k is the number of iterations, P is the parent population, xi is one 
of the individuals of the population and n is the total number of individuals (Figure 3.2).  
Each individual is represented by 𝑥𝑖 = [𝑎1, … , 𝑎𝑚] where 𝑎𝑗 is one of the optical properties 
that needs to be solved out of m optical properties.  
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The properties of the individual are then recombined with another individual in the 
parent population.  This then becomes the beginning of the child population that contains 
𝐶𝑘 = [𝑥1
𝑐𝑜𝑚𝑏𝑥2
𝑐𝑜𝑚𝑏 , … 𝑥>𝑛
𝑐𝑜𝑚𝑏]  Afterward a mutation occurs to each property for each of the 
individuals in the child population where 𝑎𝑗
𝑚𝑢𝑡 = 𝑎𝑗
′ + 𝜎𝑗 ∙ 𝑁𝑗(0,1).  Sigma represents the 
mutation step size of the jth individual and Nj(0,1) is a random number from a normalized 
distribution.  After the mutations are completed the forward model is run and the outcome 
is compared to the measurement data taken in the experiment.  The objective function 
for each child is found and the n lowest objective values are chosen for the new population 
for the next iteration.  This is repeated until one individual reaches a threshold for the 
objective function value.83 
 The forward model for the ES is based on reflectance measurements and is 
dependent on the absorption coefficient (μa), the reduced scattering coefficient (μs’), and 

































+ 𝑑2  (3.4) 
𝜇𝑒𝑓𝑓 =  √3𝜇𝑎𝜇𝑠′   (3.5)   𝜇𝑡
′ = 𝜇𝑎 + 𝜇𝑠
′    (3.6) 
 
where μeff is the attenuation coefficient, μt’ is the transport coefficient and A is the internal 
reflection parameter that takes into account the reflective index mismatch at the air-tissue 
interface.83  
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 To determine the initial condition of the static reconstruction only a fraction of the 
subject data was used in the evolutionary strategy.  The patient interface on the DDOT 
system has four concentric rings.  Only the data acquired from the second ring of the 
patient interface was used for the ES method.  The second ring was used since this was 
the ring that was most likely to have the least trouble making complete contact with the 
subject’s breast and therefore, would have the least artifacts so that the ES method would 
not be influenced by bad data.  In addition, this increases the speed of the ES code by 
reconstructing a uniform 2D area instead of a 3D volume. 
3.3.3 Data Point Selection 
 The data point selection method had a number of criteria that needed to be 
considered such as: 
1. Keeping the same number of data points for the tumor-bearing and healthy breast. 
2. Keeping the same number of data points for all time points in the longitudinal study. 
3. Identifying and removing irrelevant data points. 
4. Automate the removal process. 
In many cases, there are sources or detector fibers that were either not calibrated 
properly, not making contact with the patient’s skin, or just not working properly.  Yet, if 
we look at the target measurement divided by the reference measurement, such as in 
Figure 3.3, the poor data points can be identified.  In Figure 3.3A, there is an example of 
the calculated data for all source-detector pairings for a single wavelength.  The data 
seems to have not observable issues with data, and most likely would not have issue 
during reconstruction.  However, in Figure 3.3B, there is a whole source and detector that 
seems to have very little signal.  The aberrant data points would cause a large problem 
in the reconstruction as seen in Figure 3.4A. 
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Figure 3.3 An example of a non-problematic static data set (left) and a problematic static 
data set (right).  The magnitude is log10( 𝑀𝑡𝑎𝑟
𝜆 /𝑀𝑟𝑒𝑓
𝜆 ).  The problematic data set needs 
source 12 and detector 24 need to be removed from the reconstruction input. 
 
Figure 3.4 shows the example of a phantom measurement.  During the phantom 
measurement, source 12 (detector 24) was covered with black material.  The source 
concurrently acts as a detector.  In Figure 3.4A, there is an artifact in the location of the 
source-detector location. After the data points that are recorded when the source was 
illuminated and the data points of the corresponding detector were removed from the 
reconstruction input, the artifact disappeared from the image (Fig. 3.4B). 
 
 
Figure 3.4 Coronal slices of the same phantom measurement before (A) and after (B) 
source 12 (detector 24) had been removed from the input to the reconstruction algorithm. 
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Therefore, we developed a series of criteria to remove poor data points.  The 
magnitude of the point was calculated by using  log10( 𝑀𝑡𝑎𝑟
𝜆 /𝑀𝑟𝑒𝑓
𝜆 ) for each source-
detector pair and was examined by the criteria.  A data point was removed from the 
reconstruction if they fit under the following criteria: 
1. Source-detector points that were greater than 𝑇ℎ𝑟𝑒𝑠ℎ𝑜𝑙𝑑𝑝
1 = 𝑃𝑎𝑣𝑔 + 𝜎 ∗ 𝑃𝑆𝑡𝐷𝑒𝑣  or 
less than 𝑇ℎ𝑟𝑒𝑠ℎ𝑜𝑙𝑑𝑝
2 = 𝑃𝑎𝑣𝑔 − 𝜎 ∗ 𝑃𝑆𝑡𝐷𝑒𝑣 , where σ is a constant for the degree 
above and below the mean (Pavg) based on the standard deviation (PStDev). 
2. The median magnitude of the source across all detectors was calculated (S1, S2, 
S3…S32).  All data points for a particular source that had a median greater than 
𝑇ℎ𝑟𝑒𝑠ℎ𝑜𝑙𝑑𝑆
3 = 𝑆𝑚𝑒𝑑𝑖𝑎𝑛 + 𝛽 ∗ 𝐼𝑄𝑅𝑆𝑜𝑢𝑟𝑐𝑒or less than 𝑇ℎ𝑟𝑒𝑠ℎ𝑜𝑙𝑑𝑆
4 = 𝑆𝑚𝑒𝑑𝑖𝑎𝑛 − 𝛽 ∗
𝐼𝑄𝑅𝑆𝑜𝑢𝑟𝑐𝑒, where β is a constant for the degree above and below the median base 
on the interquartile range (IQR) and Smedian was the median of set (S1,S2, 
S3,…S32). 
3. The median magnitude of the source across all detectors was calculated (D1, D2, 
D3…D32).  All data points for a particular detector that had a median greater than 
𝑇ℎ𝑟𝑒𝑠ℎ𝑜𝑙𝑑𝐷
1 = 𝐷𝑚𝑒𝑑𝑖𝑎𝑛 + β ∗ 𝐼𝑄𝑅𝐷𝑒𝑡𝑒𝑐𝑡𝑜𝑟or less than 𝑇ℎ𝑟𝑒𝑠ℎ𝑜𝑙𝑑𝐷
2 = 𝐷𝑚𝑒𝑑𝑖𝑎𝑛 − 𝛽 ∗
𝐼𝑄𝑅𝐷𝑒𝑡𝑒𝑐𝑡𝑜𝑟 , where β is a constant for the degree above and below the median 
base on the interquartile range (IQR) and Dmedian was the median of set (D1,D2, 
D3,…D32). 
 If more than a third of the detectors for a single source meet criteria 1 then the whole 
source is removed from the reconstruction for all wavelengths.  If more than a third of the 
sources for a single detector meet criteria 1 then the whole source is removed from the 
reconstruction for all wavelengths.  The corresponding detector to a removed source is 
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removed.  If a removed detector had a corresponding source, the source is removed.  If 
the difference in the percentage of data points removed was greater than 7% for any two 
imaging time points, then σ was decreased by 0.1 until the data removal fit the condition 
or the lowest percent difference was found. The algorithm was applied to all the images 
of a single patient to assure that they were pre-processed in the same way.  Afterwards 
the modified input files were used for the reconstruction. 
The mean and standard deviation were considered for data points because using the 
above thresholds would remove any outliers or near outliers from the average of the data 
(criteria 1).  The median of each source and detector was found to avoid influences of 
single data points that would be removed by criteria 1.  Then the outliers of these medians 
were used to remove just sources or detectors that were vastly different from the rest of 
the sources or detectors (criteria 2&3). 
The percent difference was chosen around 7% since there needed to be some 
flexibility on the amount of data used per image, but this percent difference still need to 
be low.  The overall aim was to have a percent difference less than 5%, but for the 
algorithm this was increased slightly since 5% was sometimes difficult to achieve.  The 
percent difference was due to the different source-detector points that would be removed 
from the different time points since different sources would pose problems at different 
time points.  Therefore, the same amount of data removal from each image was extremely 
difficult to achieve.  If there the same points were removed from each image, the majority 
of the data would be removed and could not be used for reconstruction. 
The constants σ and β were tunable before starting the algorithm.  The tunable 
parameters were necessary for two reasons.  One, not all subjects, would reach the 
   55 
 
percent difference between two images threshold and the initial parameters would need 
to be changed.  Also, if the parameters were too conservative (i.e. σ = 2 and β = 1.5) the 
majority of the data could be removed from the reconstruction, which would yield poor 
results.  Therefore, the recommended values for the parameters should be σ > 2 and β > 
1.5.  Otherwise, the algorithm would start removing relevant data that statistically would 
not count as an outlier. 
3.4 Discrete Cosine Transform Reconstructions 
The traditional method for optical image reconstructions are element based, which 
means the number of unknowns in the problem are the number of elements in the mesh.  
However, there are usually less measurements available then unknowns in practical 
applications causing a highly ill-posed problem.  The element based reconstruction 
methods are then sensitive to measurement noise, the initial guess, and the regularization 
parameter.  The regularization parameter would have to be optimized for each mesh and 
since the current experiment involves multiple subjects each with different size meshes, 
an efficient method for determine the regularization parameter for multiple meshes was 
not possible.  As seen in Figure 3.5B, the regularization parameter also caused a blob 
formation within the center of the reconstructed image, which made tumor positioning 
difficult to determine.  Therefore, we changed over to a DCT Reconstruction method for 
our static breast reconstructions. 
The reduced space basis function neural network method for the DOT image 
reconstruction was previously developed in our lab.  Briefly, this method uses a basis 
function to reduce the solution space, so instead of solving each element which can range 
from the 8k to10k elements, the algorithm now solves the basis function, which reduces 
   56 
 
the unknowns to about 1000.  The basis function of discrete cosine transformation (DCT) 
was used.84 
 
3.5 Static Image Improvement  
 
 
Figure 3.5 Comparisons of traditional imaging methods, DOT images, and improvements 
made to the reconstruction scheme. A 47 year old pre-menopausal women who was 
diagnosed with poorly differentiated ductal carcinoma with a tumor of about 2 cm located 
in the 11 o’clock position 6 cm behind the nipple.  (A) Images show pre-therapy images 
taken from different modalities. (B) Sagittal (3 cm from center) and coronal slices (6 cm 
from nipple) are shown using the original code.  (C) Same sagittal and coronal slices as 
above, but reconstructed using DCT code with initial condition. All images are baseline 
imaging for the tumor-bearing breast (with the exception of PET). 
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 We now use a DCT reconstruction algorithm that solves for a set number of DCT 
components instead of solving for each individual mesh element.  This has eliminated the 
need for modifying the regularization parameter, and has increased the speed of 
reconstruction.  We also started to use an evolution strategy algorithm to determine the 
initial condition parameters of the reconstruction.  Figure 3.5 shows the how the baseline 
imaging for a single patient has changed from the original to the current protocol.   
In the pre-therapy images (fig. 3.5A), the tumor is visible in all three images 
modalities: US, MG, and PET-CT.  The tumor was located in the 11 o’clock position in the 
right breast 6 cm from the nipple.  In the original DOT images (fig 3.5B), the tumor appears 
in the center and does not correlate with the other imaging.  Yet, in Figure 3.5C, we can 
see the tumor in the 11 o’clock position about 6 cm from the nipple.  Therefore, the 
addition of these pre-processing tools has assisted in improving the DOT static images.  
  
3.6 Post-processing 
3.6.1 Volume of Interest Selection 
 
Figure 3.6 Flow diagram of quantification of static images.  The VOI are all the voxels 
that have a value of M-SD < Vi< M. 
 
After the reconstructions were performed the images were analyzed.  To quantify 
the images, a semi-automated custom written program was used to locate the tumor.  A 
user would look at DOT images and asked to locate the tumor (Figure 3.6).  In order to 
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reduce bias, the algorithm then looked for the maximum value (M) within a 2cm radius.  
The location of the maximum location was ?̅?𝑚𝑎𝑥 = (𝑥𝑚𝑎𝑥 , 𝑦𝑚𝑎𝑥 , 𝑧𝑚𝑎𝑥).  Additionally, the 
standard deviation (SD) of the volume was calculated.  The volume of interest then 
became all voxels with value Vi within the region that satisfied the condition M-SD ≤ Vi ≤ 
M.  Then the weighted average of the volume was taken.  To calculate the healthy breast 
the weighted average of the whole volume was used.  The normalized values were the 
tumor region divided by the healthy breast values.   
 
3.6.2 Features 
 The reconstructions solve for oxy-hemoglobin ([HbO2]), deoxy-hemoglobin ([Hb]), 
and water fraction (WF).  Total hemoglobin ([HbT]) was calculated summing [HbO2] and 
[Hb] ([𝐻𝑏𝑇] = [𝐻𝑏𝑂2] + [𝐻𝑏]).  Oxygen saturation (SO2%) was calculated using: 




The normalized values were calculated in two ways.  First, the parameters were 
divided by the parameter values for the healthy breast ([HbO2]T/H, [Hb]T/H, etc.).  Second 
the parameters were divided by the weighted average for the non-tumor region in the 
tumor bearing breast ([HbO2]T/nT, [Hb]T/nT, etc.).  Additionally, the percent change was 
calculated from the baseline imaging for both the original optical features and the 
normalized values (i.e. %Δ[HbO2], %Δ[Hb]T/H, etc.). 
 
3.7 Conclusion 
 By utilizing the DCT code and the source-detector removal conditions the quality 
and accuracy of the image was greatly improved.  The automated pre-processing and 
batching all of a single patients images saves time and allows for consistency.  
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Additionally, we have established a method to extract the tumor region without 
interference from artifacts that also reduces the bias of the user.  Then we analyzed how 
the above mention features correlated to the pathological response of the subject and 
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Chapter 4: Static DOT Results                              | 
4.1 Introduction 
Diffuse optical tomography (DOT) can create 3D maps of various tissue parameters 
using transmission measurements with non-ionizing, near-infrared light.  From these 
measurements, endogenous chromophores such as oxyhemoglobin, deoxyhemoglobin, 
water, and lipid can be used to differentiate malignant from normal tissue.25, 37-39 
Due to the sensitivity of optical imaging, multiple groups have employed this technology 
for monitoring and predicting response to NACT.  Ueda et. al. correlated the pCR rates 
to baseline tumor oxygen saturation measurements by using a handheld spectroscopic 
measurement system.85 A subset of these patients received NACT combined with 
bevacizumab or trastuzumab.  They observed an elevated baseline oxygen saturation 
(SO2%) level corresponded highly with a pCR for treatment.  Zhu et. al. observed 32 
subjects undergoing NACT using a combined ultrasound DOT imaging.58, 71, 78, 79  Subject 
received several different NACT regiments.  They report higher baseline total hemoglobin 
concentrations ([HbT]) values and the greatest decrease in [HbT] levels for pCR and near-
pCR subjects.58   
Pakalniskis et. al. also looked at optical changes during NACT in 11 patients who 
received 4 different NACT regimens using a frequency domain DOT system.57    They 
demonstrated a longitudinal decrease in total hemoglobin levels in pCR subjects but not 
non-pCR subjects. More recently Jiang et. al., looked a 19 patients that received 5 
different therapies, including a subject on Avastin.80  Employing a full-tomographic 
frequency domain system they reconstructed images of [HbT], SO2%, and water fraction 
(WF) of the tumor bearing breast.  Subjects that had a pCR showed an early percent 
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decrease in [HbT].   Several groups26, 57, 59, 72-81 observed that [HbT] levels significantly 
decreases with pCR (p=0.001)76,74; and changes can occur as early as 1 week after 
starting NACT, with tumor Hb levels dropping 33% +/-7% in responders vs. non-
responders (18% +/- 10%: z=0.008).76 
Falou et al86 observed 15 patients using diffuse optical spectroscopy for five time 
points during treatment.  There were various chemotherapy regimens employed including 
chemoradiation for two subjects.  One week after treatment they observed an initial 
increase in deoxy-hemoglobin concentrations ([Hb]), oxy-hemoglobin concentrations 
([HbO2]), WF, [HbT], and tissue optical index in responding patients, followed by a drop 
the whole breast.  Conversely, poor response patients showed an initial decrease one 
week after treatment initiation followed by an increase optical parameters.  A somewhat 
different observation was made by Soliman et. al. and Falou et. al. Employing DOS, they 
found an initial increase followed by a decrease in [HbT] during the first four weeks of 
treatment in patients that achieved a pCR after 6 months of NACT.77, 86    
However, all of these previous studies have included patients on multiple different 
heterogeneous NACT regimens. 57-60, 73, 74, 77, 79-81, 86 Some studies even included 
chemoradiation therapy. 77, 86 Using different treatment regimens for patients in the same 
cohort may confound some of the obervations. For example, different drugs have differing 
anti-angiogenic effects and may affect optical signals in disparate ways. Only recently, 
Schaafsma et. al.87  reported on results found in 22 patients who were all treated with the 
same NACT protocol. All patients received six cycles of docetaxel, doxorubicin, and 
cyclophosphamide (TAC) with or without zoledronic acid. Using a non-tomographic 
diffuse optical spectroscopy system they investigated the tumor bearing breast. They 
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found a statistically significant difference in the decrease in oxy-hemoglobin and deoxy-
hemoglobin concentrations after the first cycle of NACT between those that achieved a 
pCR versus those with a partial response. No response subjects had an overall percent 
increase in hemoglobin concentration even to the mid treatment time point. Only 4 
patients had a pCR. While results are promising, the low enrollment of complete 
responders makes it less significant.87 
The study presented in this chapter differs from all previous studies in 3 major 
aspects. First, all patients follow the same NACT regimen, a standard 
taxane/anthracycline-based therapy. Second, the number of patients enrolled for this 
project (40) is one of the largest number of patients to be evaluated in an optical imaging 
NACT study to date.  Third, our optical imaging system performs tomographic 
measurements on both breasts simultaneously, allowing for a direct comparison of the 
tumor bearing breast and the non-tumor bearing breast of the same patients.  
Since there is sufficient evidence to suggest early changes in optical properties 
during NACT, we designed a pilot study to monitor tumor progression at six time points 
throughout treatment.  We observed 40 women who all underwent the same 
chemotherapy regimen using a dual breast DOT system.  We examined three 
dimensional tomographic images of both the tumor-bearing and contralateral breast.  We 
quantified and analyzed the progression of the tumor over time and correlated 
chromophore concentrations to the RCB score of each patient. 
 
4.2 Methods 
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We employed methods found in chapter 3 for the data pre-processing and analysis 
in this chapter.  Briefly, we looked at five parameters: [HbO2], [Hb], WF, total hemoglobin 
([HbT] = [HbO2] + [Hb]), and oxygen saturation (SO2% = [HbO2]/ ([HbO2] + [Hb]) ).  The 
normalized values were divided by the parameter values for the healthy breast ([HbO2]T/H, 
[Hb]T/H, etc.) and divided by the weighted average for the non-tumor region in the tumor 
bearing breast ([HbO2]T/nT, [Hb]T/nT, etc.).  Additionally, the percent change from the 
baseline time point for each of the above mention parameters. 
 
4.3 Results 
4.3.1 Patient Summary 
 There were forty women recruited and imaged for the study with four subjects 
being excluded due to drop outs or machine malfunctions.  Table 2.2 show a subject 
summary of the patients and their pathological response.  Also, Table 2.3 show a 
summary of the number of subjects that were included in the analysis for each week for 
each response group. 
4.3.2 Case Studies 
 The first subject is a 66 year old post-menopausal woman with poorly differentiated 
invasive ductal carcinoma.  Her baseline tumor had a maximum clinical exam dimension 
of 2.3 cm.  She had an RCB of 0.  Her DOT images show a clear enhancement at the 
baseline time point in the right tumor bearing breast (Figure 4.1A).  Yet, after the baseline 
imaging, there are no clear enhancements in either breast.  The normalized quantified 
data shows a steep decrease by week 2 for [HbO2](T/H), [HB] (T/H), and [HbT] (T/H) (Figure 
4.1C).  SO2% shows a slight decrease by week 2, but WF does not show much change 
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throughout the treatment.  After the beginning of AC there seems to be another decrease 
in [HBO2](T/H), [HB](T/H), and [HbT](T/H).  The clinical exam measurement correlate well with 
the change in most of the parameters in which the tumor is no longer palpable by week 
4.   
 
Figure 4.1 Two case studies of a subject with an RCB of 0 and a subject with an RCB of 
2.7 (partial response).  The DOT images for sagittal slices of the tumor bearing and 
contralateral breast in for the pCR subject (A) and the subject with the partial response 
(B).  Quantified data showing the normalized value for each time point with the clinical 
exam tumor measurements for both the pCR (C) and partial responding subject (D).   
 
 The second subject is a 46 year old pre-menopausal subject with poorly 
differentiated invasive ductal carcinoma.  Her baseline tumor was 3.8 cm based on clinical 
exam measurements.  She had a partial response to treatment with an RCB 2.7.  The 
DOT images for this subject show an enhancement in the left tumor bearing breast that 
is visible throughout treatment (Figure 4.1B).  The quantified data reveals an increase in 
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all the parameters at the second time point (Figure 4.1D).  Beyond week 2 the value of 
each of the parameters remain steady.  The clinical exam measurements show that the 
tumor is no longer palpable by W0AC, but the subject still showed traces in the tumor 
during the AC portion of the treatment.  The remaining excised tumor was still 1.4 cm in 
diameter. 
4.3.3 Optical features during NACT 
 Table 4.1 shows a summary of of each feature for pCR and non-pCR subjects for 
each imaging time point.  The p-value for each t-test performed between the subject 
groups is shown and highlighted in yellow if there is statistical significance.  Here, we 
identify what features will that assist in determining the pCR subjects. The baseline and 
week 2 time points show the most features with statistical significance between response 
groups. 
  For baseline imaging, the more promising features that showed statistical significance 
between subject groups were [HbO2](T/H), SO2%(T/H), and SO2%(T/nT).  The pCR group 
showed higher normalized [HbO2](T/H) and SO2%(T/H) compared to non-pCR with statistical 
significance of p = 0.03 and p = 0.02, respectively.  For normalized SO2%(T/nT) pCR 
subjects were 1.12 ± 0.1 and non-pCR subjects were 1.06 ± 0.05 with a p-value of 0.03 
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Table 4.1 Summary of features for each time point and the p-value for the t-test between 
pCR and non-pCR subjects. 
 
  Tumor Region Normalized (T/H) Normalized (T/nT) 




] 56.07 ± 10.64 48.84 ± 14.94 0.13 2.84 ± 0.80 2.20 ± 0.80 0.03 2.60 ± 0.61 2.18 ± 0.72 0.08 
[Hb] 19.93 ± 4.05 19.30 ± 6.08 0.73 2.00 ± 0.38 1.97 ± 0.89 0.89 1.87 ± 0.35 1.81 ± 0.59 0.74 
WF 0.53 ± 0.07 0.54 ± 0.04 0.82 1.04 ± 0.10 1.02 ± 0.09 0.45 1.04 ± 0.02 1.03 ± 0.02 0.19 
[HbT] 75.90 ± 13.61 67.82 ± 17.51 0.15 2.55 ± 0.63 2.12 ± 0.72 0.07 2.35 ± 0.49 2.05 ± 0.61 0.14 
SO
2




] 34.68 ± 12.43 51.65 ± 16.32 0.003 1.81 ± 0.93 2.40 ± 0.88 0.07 1.68 ± 0.53 2.31 ± 0.87 0.02 
[Hb] 16.58 ± 6.21 20.05 ± 6.53 0.14 1.57 ± 0.56 2.01 ± 0.69 0.06 1.55 ± 0.38 1.95 ± 0.63 0.05 
WF 0.52 ± 0.05 0.53 ± 0.04 0.52 1.02 ± 0.12 1.01 ± 0.08 0.88 1.02 ± 0.02 1.04 ± 0.03 0.02 
[HbT] 49.39 ± 16.11 70.91 ± 21.06 0.004 1.66 ± 0.72 2.25 ± 0.80 0.04 1.57 ± 0.44 2.18 ± 0.78 0.02 
SO
2




] 41.98 ± 14.98 41.97 ± 13.34 1.00 2.10 ± 0.40 2.03 ± 0.71 0.75 2.07 ± 0.39 2.05 ± 0.56 0.90 
[Hb] 19.36 ± 7.08 16.87 ± 4.50 0.22 1.82 ± 0.65 1.79 ± 0.55 0.90 1.81 ± 0.48 1.69 ± 0.37 0.39 
WF 0.52 ± 0.03 0.56 ± 0.05 0.07 0.98 ± 0.09 1.02 ± 0.08 0.24 1.02 ± 0.02 1.02 ± 0.01 0.90 
[HbT] 60.31 ± 20.01 58.62 ± 16.73 0.79 1.96 ± 0.44 1.95 ± 0.62 0.94 1.94 ± 0.33 1.92 ± 0.46 0.85 
SO
2




] 33.82 ± 8.61 42.66 ± 16.15 0.12 1.80 ± 0.32 2.15 ± 1.00 0.29 1.84 ± 0.34 2.08 ± 0.83 0.39 
[Hb] 17.36 ± 6.46 18.08 ± 8.03 0.81 1.73 ± 0.49 1.95 ± 1.10 0.55 1.67 ± 0.45 1.84 ± 0.79 0.52 
WF 0.53 ± 0.05 0.53 ± 0.03 0.71 1.02 ± 0.12 1.00 ± 0.08 0.59 1.01 ± 0.01 1.02 ± 0.02 0.13 
[HbT] 49.73 ± 12.05 60.47 ± 22.36 0.17 1.73 ± 0.32 2.07 ± 0.96 0.29 1.73 ± 0.33 1.99 ± 0.77 0.31 
SO
2




] 38.18 ± 9.33 41.24 ± 14.55 0.53 2.04 ± 0.65 1.92 ± 0.68 0.65 2.02 ± 0.65 1.90 ± 0.59 0.61 
[Hb] 20.65 ± 7.54 16.44 ± 5.85 0.09 2.10 ± 1.06 1.62 ± 0.49 0.10 1.95 ± 0.67 1.66 ± 0.48 0.16 
WF 0.52 ± 0.03 0.55 ± 0.05 0.15 1.01 ± 0.04 1.03 ± 0.12 0.60 1.02 ± 0.01 1.02 ± 0.02 0.85 
[HbT] 56.98 ± 12.75 57.03 ± 18.09 0.99 1.99 ± 0.66 1.81 ± 0.58 0.43 1.94 ± 0.60 1.81 ± 0.52 0.53 
SO
2




] 39.73 ± 7.55 40.39 ± 9.97 0.88 2.15 ± 0.60 1.95 ± 0.56 0.43 1.80 ± 0.35 1.85 ± 0.50 0.82 
[Hb] 14.72 ± 1.94 16.08 ± 4.49 0.45 1.64 ± 0.28 1.66 ± 0.42 0.93 1.52 ± 0.14 1.60 ± 0.40 0.61 
WF 0.54 ± 0.04 0.54 ± 0.04 0.99 1.01 ± 0.08 1.02 ± 0.09 0.82 1.02 ± 0.01 1.02 ± 0.02 0.90 
[HbT] 54.15 ± 7.23 56.44 ± 13.24 0.67 1.98 ± 0.49 1.85 ± 0.47 0.54 1.71 ± 0.28 1.77 ± 0.45 0.74 
SO
2
% 71.67 ± 4.32 70.37 ± 3.32 0.42 1.08 ± 0.07 1.04 ± 0.06 0.15 1.05 ± 0.02 1.04 ± 0.04 0.45 
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Figure 4.2 Baseline imaging comparing values for [HBO2](T/H), [HBT] (T/H), and SO2%(T/H) 
between pCR and non-pCR subjects (Left).  Similarly baseline values for [HBO2](T/nT), 
[HBT] (T/nT), and SO2%(T/nT) (Right).  Asterisk denotes statistical significance (p<0.05).   
 
 As for week 2 imaging, [HbO2], [HbT], SO2%, [HbT](T/H), [HbO2](T/nT), [Hb](T/nT), 
WF(T/nT), and [HbT](T/nT) were all statistically significant between response groups.  For 
each of these aforementioned DOT parameters, the pCR group had lower concentrations 
compared to the non-pCR group (Table 4.1). Figure 4.3 shows the three features at the 
week 2 time point with the lowest p-values: [HbO2], [HbT], and normalized WF(T/nT).  Each 
of these parameter had higher values for the non-pCR group compared to the pCR 
subjects. 
 
Figure 4.3 Comparison of pCR and non-pCR subjects at week 2 using imaging 
parameters that showed the highest correlation to RCB score in Table 3.  An asterisk (*) 
denotes p< 0.05 and (#) denotes p < 0.01. 
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There were two other time points besides baseline and week 2 that showed 
statistical significance in a parameter.  At week 4 SO2%(T/H) showed statistical significance 
between pCR and non-pCR subjects (p=0.01).  Also, at week 2AC SO2% showed 
statistical significance with non-pCR subjects having higher SO2% levels than pCR 
subjects. 
4.3.4 Baseline and Week 2 Correlation Coefficient 
Table 4.2 Summary of correlation coefficients, and p-values of the linear regression of 
the RCB scores versus the baseline and week 2 parameters in the tumor region and 





Tumor Region Normalized(T/H) 
Normalized 
(T/nT) 
R p-value R p-value R p-value 
Baseline 
[HbO2] -0.29 0.09 -0.36 0.03 -0.33 0.052 
[Hb] -0.11 0.53 -0.03 0.85 -0.08 0.62 
Water% -0.01 0.97 -0.07 0.67 -0.25 0.14 
[HbT] -0.28 0.10 -0.29 0.08 -0.28 0.10 
SO2% -0.10 0.57 -0.31 0.07 -0.33 0.0504 
Week 2 
[HbO2] 0.50 0.003 0.32 0.06 0.41 0.02 
[Hb] 0.15 0.40 0.21 0.23 0.23 0.18 
Water% 0.18 0.31 0.04 0.80 0.46 0.007 
[HbT] 0.46 0.006 0.34 0.05 0.41 0.02 
SO2% 0.36 0.04 0.02 0.92 0.07 0.68 
 
 Since most parameters showed the greatest statistical significance at baseline and 
week 2 we looked at the correlation coefficient for these time points.  The parameters for 
the tumor region and normalized tumor region were correlated to the continuous RCB 
score and the statistical significance of the correlation was calculated.  For baseline 
imaging the correlation that was the highest was the [HbO2](T/H).  This had a negative 
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correlation coefficient which suggests that subjects that will have a low RCB or a pCR 
have higher [HbO2](T/H) . 
All features in for the baseline imaging had negative slopes and the all the features 
for week 2 had positive slopes.  The feature [HbO2](T/H) had the only statistically significant 
correlation at baseline.  In Figure 4.4 the linear regression analysis for RCB score versus 
[HbO2](T/H) is shown for both baseline and week 2 imaging.  For baseline there is a 




Figure 4.4 Linear regressions of the RCB score versus [HbO2](T/H) at baseline imaging 
(left) and week 2 (right).   
 
4.3.5 Percent change from Baseline Imaging 
 After observing the absolute and normalized parameters, we looked at how these 
parameters change over time with respect to the baseline.  In Table 4.3, the percent 
change (%Δ) of each parameter from the baseline imaging is shown.  Here we can 
observe not only statistical significance between pCR and non-pCR subjects for some 
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features at the week 2 point but for all other time points as well, with the exception of the 
pre-surgical time point.  However, week 2 and week 0AC have the most parameters with 
statistical significance.   
Table 4.3 Summary of the percent change of each parameter from the baseline and the 
statistical analysis of pCR versus non-pCR subjects. 
 
  Tumor Region Normalized (T/H) Normalized (T/nT) 
Time 
point 




] -36.44 ± 23.54 19.63 ± 69.58 0.01 -35.22 ± 30.91 22.94 ± 62.96 0.002 -33.48 ± 25.46 16.23 ± 52.63 0.003 
%Δ[Hb] -14.31 ± 30.64 14.76 ± 49.24 0.07 -20.68 ± 25.16 16.45 ± 49.12 0.01 -13.64 ± 29.00 18.14 ± 45.64 0.03 
%ΔWF -0.18 ± 14.37 -0.06 ± 9.13 0.98 -1.34 ± 15.29 -0.10 ± 11.86 0.63 -2.41 ± 1.85 0.59 ± 3.29 0.01 
%Δ[HbT] -33.30 ± 22.36 16.12 ± 62.42 0.01 -34.03 ± 27.44 18.93 ± 58.11 0.003 -31.43 ± 23.32 15.33 ± 50.14 0.004 
%ΔSO
2




] -25.63 ± 25.75 0.91 ± 73.97 0.24 -25.60 ± 19.66 6.59 ± 66.61 0.11 -19.74 ± 25.19 5.98 ± 54.71 0.13 
%Δ[Hb] -2.58 ± 31.22 -4.36 ± 48.70 0.91 -9.26 ± 33.54 1.98 ± 50.88 0.58 -3.16 ± 31.01 -0.61 ± 36.25 0.84 
%ΔWF -3.20 ± 5.53 4.15 ± 11.74 0.05 -3.25 ± 13.22 0.84 ± 11.69 0.32 -1.72 ± 2.02 -1.09 ± 2.72 0.48 
%Δ[HbT] -20.97 ± 24.90 -1.64 ± 66.33 0.34 -23.32 ± 20.64 4.50 ± 62.89 0.16 -17.38 ± 22.35 3.13 ± 49.57 0.19 
%ΔSO
2





] -37.81 ± 19.76 -6.79 ± 38.72 0.02 -33.24 ± 21.70 0.04 ± 36.19 0.01 -27.66 ± 19.06 -2.27 ± 30.40 0.02 
%Δ[Hb] -9.19 ± 36.46 -6.14 ± 27.71 0.80 -12.87 ± 25.66 -0.55 ± 27.02 0.38 -12.12 ± 30.73 0.90 ± 22.25 0.19 
%ΔWF -1.89 ± 7.91 -1.13 ± 9.42 0.83 -2.05 ± 11.49 -2.13 ± 10.88 0.97 -2.55 ± 1.74 -0.73 ± 1.95 0.02 
%Δ[HbT] -32.32 ± 20.42 -8.15 ± 32.52 0.04 -29.84 ± 20.21 -1.51 ± 30.87 0.02 -26.71 ± 16.79 -2.06 ± 26.46 0.01 
%ΔSO
2





] -26.70 ± 31.86 -5.38 ± 48.26 0.20 -20.58 ± 37.22 -2.23 ± 39.60 0.17 -19.30 ± 30.50 -4.99 ± 36.24 0.28 
%Δ[Hb] 8.55 ± 49.15 -5.71 ± 39.99 0.39 10.17 ± 66.68 -4.31 ± 36.28 0.39 3.30 ± 38.43 0.72 ± 33.66 0.85 
%ΔWF -4.71 ± 6.22 2.98 ± 12.39 0.06 -4.02 ± 8.99 0.83 ± 15.62 0.34 -1.86 ± 1.91 -1.11 ± 2.38 0.38 
%Δ[HbT] -19.46 ± 32.74 -7.76 ± 42.00 0.43 -14.48 ± 41.87 -4.99 ± 35.07 0.47 -15.74 ± 29.92 -4.67 ± 32.45 0.36 
%ΔSO
2





] -20.58 ± 29.34 0.69 ± 76.27 0.48 -13.71 ± 39.87 7.88 ± 68.13 0.42 -28.44 ± 23.88 -0.25 ± 60.54 0.25 
%Δ[Hb] -19.03 ± 18.27 -2.34 ± 62.01 0.49 -10.91 ± 25.15 2.28 ± 56.59 0.65 -22.05 ± 15.64 1.30 ± 50.73 0.25 
%ΔWF -0.04 ± 7.95 0.83 ± 9.28 0.83 -1.88 ± 12.55 -1.14 ± 11.09 0.72 -1.73 ± 2.67 -1.21 ± 2.71 0.66 
%Δ[HbT] -20.50 ± 24.52 -1.74 ± 70.05 0.50 -13.18 ± 34.90 4.69 ± 62.78 0.51 -26.71 ± 21.26 -0.06 ± 56.84 0.24 
%ΔSO
2
% 0.49 ± 5.96 0.54 ± 10.09 0.99 -2.31 ± 9.58 0.76 ± 9.22 0.35 -3.26 ± 4.41 -2.41 ± 3.97 0.64 
 
The non-normalized percent change tumor measurements had the most 
statistically or near statistically significant features.  Figure 4.5 presents the features that 
were statistically significant at least at the week 2 time point.  Each features shows an 
increase in the percent change for the non-pCR subjects and a percent decrease for the 
pCR subjects at the week 2 time point.  The %Δ[HbO2] (Figure 4.5A) shows statistical 
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significance at only the week 2 and week 0AC time points.  The pCR subjects seem to  
not change much after the initial decrease at week 2 and then there is a slight increase 
occurring after week 12 (week 0AC).  The %Δ[Hb] shows no statistical significance 
beyond the second week of treatment (Figure 4.4B). The %Δ[HbT] (Figure 4.4C) had a 
similar trend as the %Δ[HbO2].  Last, %ΔSO2% shows statistical significance between 
groups for all time points with the exception of the pre-surgical time point.  The pCR 
subjects show a decrease in %ΔSO2%, which begins to increase again after AC began 
to be administered (week 12).  The non-pCR subjects show that %ΔSO2% slightly 
decreases by week 4 but continues to increase throughout the rest of treatment. 
 
Figure 4.4 Longitudinal line plots of pCR and non-pCR subjects for %Δ[HbO2] (A), 
%Δ[Hb] (B),%Δ[HbT] (C), and %ΔSO2% (D). 
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At the week 2 time point, the percent change in [HbO2](T/H), [Hb](T/H), and [HbT](T/H) 
were statistically significant, as well as, all the features for the (T/nT) normalization 
scheme (Table 4.3).  For each of these features the pCR group experienced a percent 
decrease, while non-pCR subjects demonstrated an increase in the normalized features. 
For the Week 0AC time point, the statistically significant features normalized to the 
healthy breast for the Week 0AC time points were the percent change in [HbO2](T/H), 
[Hb](T/H), and [HbT](T/H).  As for the (T/nT) normalization scheme, in [HbO2](T/nT), WF(T/ nT), 
and [HbT](T/ nT) showed statistical significance between the pCR and non-pCR groups.  
Last, the percent change in SO2%(T/H), showed statistical difference at the Week 2AC time 
point. 
4.3.6 Correlation Coefficient of the Percent Change 
 Similar to the baseline and week 2 analysis, we observed the correlation coefficient 
for the percent change from the baseline imaging for all parameters.  The percent change 
in the tumor region is significantly correlated with the RCB score for %Δ[HbO2], %Δ[Hb], 
and %Δ[HbT] for week 2.  The %ΔWF is correlated only for the week 4 and week 2AC 
time point (Table 4.4). 
For the (T/H) normalized parameters, the strongest correlated parameters for week 2 
are %Δ[HbO2](T/H), %Δ[Hb2](T/H), and %Δ[HbT](T/H).  However, beyond the second week, 
%Δ[HbO2](T/H) shows significant correlation at week 4 and the week 2AC time points.  
Additionally, %Δ[HbT](T/H) has significant correlation at week 4, while %ΔSO2%(T/H) is 
strongly correlated at Week 2AC.  Only %Δ[Hb](T/H) in the pre-surgical time point showed 
statistical significance.  
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Table 4.4 Summary of linear regression analysis of RCB score versus the percent change 





Tumor Region Normalized(T/H) Normalized (T/nT) 
R p-value R p-value R p-value 
Week 2 
%Δ[HbO2] 
0.5 0.003 0.51 0.002 0.55 0.001 
%Δ[Hb] 0.37 0.03 0.43 0.01 0.34 0.051 
%ΔWF 0.1 0.59 0.04 0.83 0.52 0.002 
%Δ[HbT] 0.5 0.003 0.51 0.002 0.52 0.002 
%ΔSO2% 0.27 0.12 0.28 0.11 0.4 0.02 
Week 4 
%Δ[HbO2] 0.29 0.1 0.38 0.03 0.36 0.04 
%Δ[Hb] 0.11 0.53 0.24 0.16 0.14 0.45 
%ΔWF 0.34 0.05 0.13 0.46 0.21 0.24 
%Δ[HbT] 0.26 0.14 0.35 0.04 0.32 0.07 
%ΔSO2% 0.19 0.28 0.07 0.69 0.3 0.09 
Week 
0AC 
%Δ[HbO2] 0.31 0.09 0.34 0.07 0.36 0.05 
%Δ[Hb] 0.11 0.57 0.25 0.18 0.25 0.18 
%ΔWF 0.13 0.48 0.03 0.85 0.34 0.06 
%Δ[HbT] 0.31 0.09 0.36 0.05 0.4 0.03 
%ΔSO2% 0.22 0.22 0.29 0.12 0.19 0.29 
Week 
2AC 
%Δ[HbO2] 0.35 0.051 0.37 0.04 0.39 0.03 
%Δ[Hb] -0.05 0.77 -0.06 0.76 0.06 0.74 
%ΔWF 0.51 0.004 0.2 0.27 0.3 0.10 
%Δ[HbT] 0.29 0.11 0.28 0.13 0.35 0.052 
%ΔSO2% 0.3 0.10 0.44 0.01 0.32 0.08 
Pre-
surgical 
%Δ[HbO2] 0.29 0.16 0.35 0.08 0.4 0.04 
%Δ[Hb] 0.33 0.10 0.39 0.05 0.42 0.03 
%ΔWF 0.07 0.74 -0.03 0.88 0.17 0.41 
%Δ[HbT] 0.3 0.13 0.36 0.07 0.41 0.04 
%ΔSO2% -0.12 0.55 0.03 0.9 0.12 0.57 
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Figure 4.5  Linear regression of the RCB score versus the %Δ[HbO2](T/nT) (A), %ΔWF(T/nT) 
(B), %Δ[HbT](T/nT) (C), %ΔSO2%(T/nT) (D).  Solid lines show the linear fit to the data and the 
dotted lines show the 95% confidence intervals (CI) upper and lower bounds. 
 
 For the (T/nT) normalization scheme, all the parameters show high correlation at 
the week 2 time point. Figure 4.5 shows the linear correlation RCB score versus 
%Δ[HbO2](T/nT) (A), %ΔWF(T/nT), %Δ[HbT](T/nT) , and %ΔSO2%(T/nT), which all showed 
statistical significance at week 2.  Each of these displayed features have a positive 
correlation compared to RCB score.   
The features %Δ[HBO2](T/nT) and %Δ[HbT](T/nT) had statistical significance or near 
statistical significance for all the time points including the pre-surgical time point. 
4.3.7 Longitudinal Trends 
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Figure 4.6 The percent change from baseline imaging of [HBO2](T/nT) over the course of 
NACT for RCB 0 (pCR) subjects, RCB I and II subjects, and RCB III subjects.  Error 
bars represent standard error.  
 
 Since the %Δ[HbO2](T/nT) show the greatest correlation among the all the time 
points we looked at how these parameters change over the course of treatment.  In figure 
4.6, each subject group displays non-linear trends of how these parameters change over 
the course of treatment.  The RCB 0 subjects show a decrease in %Δ[HbO2](T/nT) by week 
2, but then the percent change from the baseline does not change much at the other time 
points.  The RCB I&II group shows a slight percent increase by week 2, but does not 
seem to change much from the baseline.  However, after the W0AC time point this group 
shows a percent decrease at the Week 2AC and pre-surgical time points.  Last, the RCB 
III group increases about 47%, decreases back to baseline values by Week 0AC, and 
then shows about a 31% increase by the pre-surgical time point. 
4.3.8 Predicting Tumor Response 
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 ROC curves were created for each parameter and the five parameters with the 
highest Youden index for all imaging time points as seen in Table 4.5.  These parameters 
are all during week 2 and consist of the percent change in either oxy-hemoglobin or total 
hemoglobin (normalized or otherwise).  The parameter with the highest area under the 
curve (AUC) is %Δ[HbO2](T/nT), where we observed a sensitivity of 76.9% (10/13 subjects) 
and a specificity of 90.5% (19/21 subjects).  Therefore, the overall accuracy using a cutoff 
value of -27.5% is 85.3% (29/34 subjects).  The highest sensitivity was 100% (13/13 
subjects) for %Δ[HbO2] for week 2.  The specificity for this parameter was 61.9% (13/21), 
an accuracy of 76.5% (26/34 subjects), a PPV of 61.9% (13/21 subjects), and a NPV of 
100% (13/13 subjects). 
Table 4.5 Summary of parameters with the highest Youden index values for baseline 
and week 2 imaging. 
Parameter Time 
Point 
Sensitivity Specificity Accuracy AUC PPV NPV 
%Δ[HbO2](T/nT) Week 
2 
76.9% 90.5% 85.3% 0.87 83.3% 86.0% 
%Δ[HbO2](T/H) Week 
2 
76.9% 90.5% 85.3% 0.86 83.3% 86.0% 
%Δ[HbT](T/nT) Week 
2 
84.6% 76.2% 85.3% 0.82 68.8% 89.0% 
%Δ[HbT](T/H) Week 
2 
76.9% 85.7% 82.4 0.86 76.9% 86.0% 
%Δ[HbO2] Week 
2 
100% 61.9% 76.5% 0.84 61.9% 100% 
 
4.4 Discussion 
4.4.1 Summary of Results 
 The week 2 time point shows the highest correlation for [HbO2] and [HbT] to the 
RCB score of the subject, even when the data is normalized or the percent change of the 
   77 
 
normalized values are calculated.  We found a statistical decrease in [HbT], which 
corresponds to the multiple studies done on optical NACT monitoring.26, 48, 57-60, 72-81   
Additionally, the baseline SO2%(T/H) values for pCR subjects were higher than non-pCR 
subjects.  This is similar to the work done by Ueda et. al., where they found an increase 
in SO2% in subjects that would receive a pCR to NACT.60 
However, there is statistically significant correlation between RCB score and the DOT 
parameters throughout the entirety of NACT.  Therefore, while the week 2 and even 
baseline time points may be used to evaluate the efficacy of treatment, the other imaging 
time points can also be used to determine if the subject will respond to NACT as well.  
Determining response throughout therapy can be beneficial to monitor if the tumor is still 
progressing or not.  Therefore, there can be multiple check points within the NACT to be 
able to monitor and assess treatment to assure that the patient has the optimal response 
to NACT. 
4.4.2 Physiological Explanation 
 Taxanes cause cell death by inhibited cell growth, differentiation, and proliferation 
by stabilizing microtubules within the cells.  Essentially taxanes cause an arrest in the G2 
phase of cell division prevent further maturation and proliferation.88, 89   There has also 
been evidence of taxanes inhibiting VEGF, which would suppress angiogenesis.88, 90  
Symmans et. al. demonstrated an increase in apoptosis and mitotic arrest in BC patient 
receiving paclitaxel within days of the first dose.91 Additionally in terms of early vascular 
changes, there have been studies that looked at interstitial fluid pressure (IFP) within the 
breast tumors after taxane administration,92 which is caused by the massive apoptosis of 
responding tumor cells.93  The early changes that we have observed may be caused by 
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these physiological phenomenon.  First, there was a decrease in [Hb] and [HbO2] by the 
second week of treatment for pCR subjects.  This can be caused by the antiangiogenic 
effects that taxanes have on tumors.  Also, the massive apoptosis of cancer cells could 
restore the microenvironment making the area less hypoxic and contributing to the 
decrease in [Hb].  Last, we noticed that there was a decrease for pCR subject in WF(T/nT) 
by week 2.  This could be contributed to the decrease in IFP within the tumor region 
compared to the surrounding healthy tissue in the tumor bearing breast.  Therefore, the 
early optical response of pCR subjects may possibly be contributed to the decrease in 
microvessels, hypoxia, and IFP. 
Anthracyclines stop the process of replication by preventing DNA from resealing after 
transcription.  Cyclophamide similarly works by disrupting the DNA to prevent cell growth 
and division.89  Anthracycline has shown to increase apoptosis and decrease proliferation 
in breast cancer.94  During this part of the treatment there seemed to be very little change 
to the pCR subject.  However, the RCB I/II subjects began to decrease beyond baseline 
values in [HBO2](T/nT), while RCB III subjects demonstrated and increase in [HBO2](T/nT) 
after AC treatment (refer to fig 4.6).  As a result, there seems to be no further change in 
pCR subject, the RCB I/II subjects seem to benefit from the change in chemotherapy 
agents, and the RCB III subjects seem to worsen. 
4.4.3 Conclusion 
 Early imaging time points, as other studies have suggested, are still optimal for 
determining the response of the subject.  Specifically we saw that the %Δ[HbO2](T/nT)  at 
week 2 time point yielding the highest sensitivity and specificity for determining a pCR or 
not.  Additionally, there is a positive statistically significant correlation between 
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%Δ[HbO2](T/nT) and RCB score for every time point after baseline imaging.  This suggests 
that it may be possible to monitor tumor progression throughout NACT, not only initially 
predict response.  Monitoring would be more beneficial in some patient cases.  Hence, if 
a subject is predicted to respond by the second week, but further monitoring shows that 
she has not responded as well as originally perceived, a decision could be made on 
whether to proceed with prescribe chemotherapy agent or change drugs to help optimize 
the subject’s outcome.  These results are promising since it could lay the ground work for 
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Chapter 5: Dynamic Data Processing            | 
5.1 Introduction 
In a previous pilot study we have shown evidence that the hemodynamic response 
to a simple breath hold can be used to diagnose breast cancer. Tumors tend to have 
inherently different time traces compared to healthy tissue.39 Here we hypothesize that 
vascular changes occur early in the treatment process and that related hemodynamic 
parameters can be used to predict NACT treatment outcome.   The different features from 
the hemodynamic traces that we extracted from the dynamic DOT imaging will be 
correlated with the pathological response of the subject.   
There are three steps that were necessary for dynamic DOT analysis: pre-
processing, image quantification, and feature extraction. 
 
5.2 Challenges to Overcome 
There were several challenges to the pre-processing procedure that needed to be 
overcome.  First, there needed to an efficient and quick method to automate the pre-
processing procedure.  Second, there were high frequency noise that made the breath 
hold trend difficult to determine.  Third, each dynamic movie reconstruction took about 24 
hours to complete, but not each breath hold was viable for analysis.  Therefore, some 
breath holds needed to be reconstructed again, so there needed to be a procedure to 
determine before the reconstruction process to determine if the breath hold was usable.  
Additionally, some detector signals would cause issues with the reconstructions and 
would need to be removed, so there needed to be a process to determine these points.  
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Last, in order to fix these issues there needed to be a means of visualizing the raw 
data and the input information for the reconstructions to see how improvements could be 
made to the pre-processing procedure.  What made data visualizing challenging was the 
enormous amount of data that we collect.  If there are 32 sources, 64 detectors, 2 
wavelengths, and a thousand frames then there are over 4 million data points to observe. 
Therefore, there were sufficient efforts made to develop techniques to visualize all of this 
data for pre-processing. 
Image quantification also needed to be improved.  Originally, for each frame of the 
reconstruction, the location of the maximum value was found and then a 1 cm diameter 
sphere around the maximum was averaged.  Each average became a data point in time 
and the changes in the reconstruction could be viewed over the course of about a minute.  
One issue with this method is that the 1 cm sphere is free to move within the breast 
volume, so the maximum value could bounce from one region to the other, which would 
not occur in typical breast tumor physiology.  Also, the tumor region usually is not confined 
to a 1 cm sphere volume or shape.  Therefore, techniques were developed to quantify the 
data to determine a stationary volume that resembled the size and shape of the tumor. 
 For the feature extraction, we needed to determine physiological parameters that 
would assist in predicting tumor response.  However, one problem was that some 
subjects could not hold their breath for the entire desired length of thirty second.  Despite 
this challenge, if a subject held their breath for only fifteen seconds, half the time 
recommended, there were still clear hemodynamic effects to the breast tissue as seen 
from our optical imaging.  Yet, this caused a large variation in the amount of time that the 
subjects could hold their breath.  Therefore, certain parameters such as, time to peak or 
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a certain percentage, full width half maximum, and time to recovery could not be analyzed.  
As a result, we looked more a parameters that were not dependent on the breath hold 




 The pre-processing procedure before running a reconstruction is outlined in Figure 
5.1.  First, the raw data was pre-processed by applying a discrete cosine transform (DCT) 
filter that uses the first 15 coefficients to reduce high-frequency noise. Then one of the 
breath holds is chosen for reconstruction and the measurement files are created.  
Measurement files contain the filtered dynamic signal for each source-detector signal and 
the averaged baseline signal, which were calculated from the raw data.  Next, the forward 
model is run in order to get the prediction measurement for the reconstruction.  The input 
files are created using the measurement files and the prediction measurement.  There 
may be an additional step in which poor detector signals are removed from the input files 
directly.  Last, the reconstruction was run. 
 
Figure 5.1 Flow diagram of how data is processed before the reconstructions are run. 
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 where λ is the wavelength, z(t) is the input to the reconstruction for time t, 
M is a measurement, and P is the prediction measurement.  M(t) tar represents the 
measurement at time t during the breath hold.  Mref is the baseline measurement taking 
as an average of the 30 seconds of data prior to the subject holding their breath.  Then 
the signals that showed a signal to noise ratio of less than 10dB were labelled for removal 
from the reconstruction.  These two steps gave the input files to the reconstruction. 
5.3.2 Automated Program 
 In order to automate and quicken the pre-processing, a simple user interface was 
designed to guide the user easily through the necessary steps to pre-process the data.  
Figure 5.2 shows the first step where the measurement files are created.  The program 
covers two stages of the pre-processing procedure.  First, the raw data is filtered and the 
measurement files are created. Second, the calculated input files are used to remove any 
potentially erroneous signals.   
 The first step for creating the measurement files is loading the raw data.  The raw 
data are kept in files that the program can automatically search through to obtain the 
desired patient and time point.  Next the all the data is for each wavelength is displayed 
as a check to make sure there are no obvious issues with the data (i.e. missing 
wavelength data due to malfunction).  Figure 5.3 shows an example of the signals from 
the raw data. 
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Figure 5.2 Flow diagram of MatLab program to create text files for reconstruction input. 
 Then the program asks for the starting frames for each breath hold.  The program 
then performs DCT filter on each of these sections of data and displays the filtered signal 
(Figure 5.4).  The filtered signal display shows the negative sum of all the detector signals. 
This has become an essential check in the dynamic reconstruction process.  Before this 
check point was established, the optimal breath hold for reconstruction was difficult to 
establish.  Since occasionally the patient might move after a breath hold or talk, there are 
sometimes motion artifacts or other issues with the breath hold.  With this MatLab 
program, we can see each breath hold at once, and determine the best one for 
reconstruction.  Otherwise, potentially, each breath hold might need to be reconstructed 
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to find the best one, which was time consuming since each reconstruction could take a 
day to complete. 
 
 
Figure 5.3 Visualization of each raw signal for an entire imaging from each source 
detector pair for each wavelength for the left and right breast. 
 
There is an option to shift the breath hold frames one way or the other.  
Occasionally, the breath hold does not start right at the beginning of the frames that we 
instructed during the subject imaging.  The subject could either start late (i.e. take their 
time beginning the breath hold) or start before we finished giving directions.  Therefore, 
this option allows us to shift the data filtered a couple of frames in order to begin the 
reconstruction at the start of the breath hold.  Once the breath hold is filtered and chosen, 
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the user can choose how to name the files and the text files are automatically saved to a 
folder. 
 
Figure 5.4 Time traces for each breath hold that shows the normalized summation of all 
the detectors for each wavelength for each breast. 
   
5.3.3 Modify Input Files 
The other option for this program is to modify the input files.  After the 
measurement files have been created and the forward model run, then the created input 
files can also be used to check for any errors in the data.  Similarly to the “creating the 
measurement” process of the program, the program has a “modify input file” process, 
which also guides the user to correct files they wish to use.  Once the files are loaded, 
each frame of the breath hold can be displayed.  In Figure 5.5 is an example of one frame 
of data for a patient that has poor signal in one of the detectors.  After the user is finished 
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looking through the frames, the program prompts whether to remove any sources or 
detectors from the reconstruction.  From the example giving in Figure 5.5, detector 54 
would need to be removed from the reconstruction, since it is showing a much lower 
signal than the rest of the data.  This process is important since aberrant detectors can 
severely impair the quality of the dynamic reconstructions.  As seen in Figure 5.6, with 
the poor detector used in the reconstruction input data, there is no visible breath hold and 
the magnitude is far above what is typically expected.  With the detector removed, the 
breath hold is visible. 
 
Figure 5.5 Visualization of input file data for each source detector pair signal for each 
wavelength for each breast (Left).  The input signal is Mtar/Mref.  Also plots of the average 
input signal for each source and each detector (Right).  Sources also act as detectors.  
The sources are represented by circles and overlay its corresponding detector signal.  
Detector 54 on the right side for both wavelengths shows a poor signal. 
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Figure 5.6 Time trace of the reconstructed results of the data seen in Figure 5.5 of the 
same breath hold with and without detector 54 removed. 
 
Despite the current Matlab program having aided in increasing the speed and 
efficiency of pre-processing the dynamic data, there are still areas that could be improved.  
At the moment these poor source or detector signals are visualized and removed 
manually.  However, the program could be improved if poor signals could be automatically 
removed. 
 
5.4 Image Reconstruction Algorithm   
The resulting data set was input to a diffusion-theory based PDE-constrained 
multispectral imaging algorithm.69 This algorithm produced 3-dimensional volumetric 
reconstructions of various tissue parameters of both breasts. In this study we focused on 
the percent change of oxy-hemoglobin concentration (%Δ[HbO2]) and percent change of 
deoxy-hemoglobin concentration (%Δ[Hb]) with respect to values observed at baseline. 
The baseline values were obtained as the average signal level over a period of 30 
seconds prior to the patient’s breath hold.  Each frame was reconstructed using the 
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previous frame as the initial guess to the reconstruction, which decreases the 
reconstruction time and improves accuracy.  The first frame starts with a uniform initial 
condition. 
5.5 Post-Processing: Image Analysis and Quantification 
 
 
Figure 5.7 A visual of how time traces are acquired from 3D imaging. First the frames of 
the 3D images are averaged (A).  The max of the averaged 3D image is found and a 
volume of half of the max is determined to become the volume of interest (VOI) (B).  Last, 
the average of the voxels in the VOI for each frame is found and plotted (C). 
 
After the reconstructions are completed, the movies are quantified.  To identify the 
area that contains the tumor in the tumor-bearing breast, we average each voxel of the 
full 3-D tomographic data set over the period of the breath hold and half the recovery 
time. This results in a single frame of 3D data (see Fig. 5.7). Within this single frame we 
determine the location ?⃗?𝑚𝑎𝑥 = (𝑥𝑚𝑎𝑥 , 𝑦𝑚𝑎𝑥 , 𝑧𝑚𝑎𝑥) of the maximum percentage change in 
deoxyhemoglobin (%Δ[Hb]max) and the value of half this change, defined as FWHM = 
%Δ[Hb]max/2. All voxels within the vicinity of ?⃗?𝑚𝑎𝑥  for which %Δ[Hb]≥ FWHM are defined as 
part of the “volume of interest” (VOI) which contains the region with the tumor.  Then for 
each time point t of the original breath-hold data, the %Δ[Hb] values of each voxel within the 
VOI is averaged to get a single data point SHb(t) = %Δ[Hb]avg(t) . This value will change from 
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time point to time point and a time-dependent curve SHb(t) can be plotted (see e.g. Fig. 
5.7). Similarly, the same process was used to determine SHbO2(t) = %Δ[HbO2]avg(t). 
 
5.6 Breath Hold Trace Improvement 
 Figure 5.8 shows an example of a breath hold for a patient before and after the 
above techniques were established.  The breath hold in the before time trace (Fig. 5.8A) 
is difficult to distinguish and shows high frequencies.  Figure 5.8B shows a much smother 
signal with a distinguishable breath hold.  This improvement was due to the use of the 




Figure 5.8 Example of a dynamic reconstruction of a baseline breath hold for a partial 
response patient using just a 10dB filter (A) and both a 10dB and DCT filter using the first 
15 coefficients (B). 
 
5.7 Feature Extraction 
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With reconstructed 3D imaging data sets of the two parameters (%Δ[Hb] and 
%Δ[HbO2]) for both breast in place, the task becomes to find suitable features in these 
images that show pronounced differences between the responders and non-responders.  
First, a MatLab program was created to automatically find key points in the breath 
hold curve.  Figure 5.9 shows the key points that were determined via this program. 
 
Figure 5.9 An example of a breath hold for both the tumor (red) and healthy (blue) 
undergoing feature extraction.  Specific points along the breath hold curve were 
determined on the curves for further calculations.  The maximum of the peak, the start 
point for the exponential fit for the recovery portion, the post 15 second after the peak, 
the initial minimum before the peak value, and the post-peak minimum value and location 
were determined.   
 
The maximum peak is found by locating the maximum value during the breath hold.  The 
15 second post breath hold value is determined 15 seconds after the peak.  To find the 
key minimum values in the graph, the local minimum before (initial) and after (post peak 
minimum) the peak were located.  Last, the exponential fit start point is the maximum 
value before the recovery portion of the curve.  This point is usually the peak value, 
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however, occasionally the breath hold would have a plateau section around the peak 
location (see Figure 5.9).  Therefore, to properly determine the exponential fit the start 
point has to occur at the edge of this plateau portion of the breath hold.  After these points 
were determined, the following features were determined. 
Since time-dependent dynamic data was obtained during a breath hold, we first 
focused on time varying features inside the tumor.  Figure 5.10 shows a plot of the time-
dependent SHb values for the VOI in one of our subjects. One can see how the SHb 
increases sharply before a maximum is reached. Once the patient starts breathing again 
SHb decreases. To capture the features of this rise and fall in a more quantitative way, we 
introduce the following parameters, many of which have been used in other dynamic 
imaging modalities before: initial enhancement (IE) of the breath hold, post-initial 
enhancement (PIE), normalized maximum value (NMV), rise slope (mrise), fall slope (mfall),  
rise rate (τrise), and  washout rate (τfall).   
Initial enhancement (IE) is a parameter often employed in functional magnetic 
resonance imaging (MRI). It is a measure of how an MRI contrast agent increases in 
signal intensity after injections.95  We adapted this parameter for DDOT by defining it as 
the ratio of the difference between the peak signal strength, Speak, and the initial minimal 




                                                                (1) 
The post-initial enhancement (PIE) is another parameter used in contrast-
enhance MRI. It is employed to determine how fast a contrast agent leaves a region an 




                                                          (2) 
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In this equation SpostBH15sec is the [HbT] value 15 seconds post breath hold mark. In 
previous studies we found that this value leads to biggest differences between non-tumor 
bearing and tumor bearing breast.23  The post-15 value was determined by using the 
value in the trace 15 seconds after the peak and normalizing it by the value of the peak.   
The rise slope, mrise, was found by using the formula for slope between two points, 
where the first point was the minimum value before the peak and the second point was 
the peak point.  The fall slope, mfall, was similarly found using the peak as the first point 
and the post-15 second point as the second.  A visualization of the above features can 
be seen in Figure 5.10. 
 
Figure 5.10 An example how several features are taken from the time trace for a single 
breast. 
 
The rise rate, τrise, was determined by fitting the rising portion of the curve to an 
exponential and taking the rate coefficient by looking at the section between the minimum 
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values before the peak to the peak value.  Similarly, the washout rate, τfall, was 
determined by fitting the recovery portion of the breath hold trace to an exponential and 
taking the rate coefficient.  The recovery portion was defined from the maximum point of 
the trace to the following minimum position.  These portions of the curve were fitted to the 
following equations: 
𝑆𝑋 = 𝐴𝑟𝑖𝑠𝑒 ∗ 𝑒
𝜏𝑟𝑖𝑠𝑒∗𝑡 
(3) 
𝑆𝑋 = 𝐴𝑓𝑎𝑙𝑙 ∗ 𝑒
−𝜏𝑓𝑎𝑙𝑙∗𝑡 
 
Where Arise and Afall were coefficients, t was the time that has passed in seconds, 
and SX is either SHb or SHbO2.  The parameters τrise and τfall were then used in the current 
analysis. 
The normalized maximum peak value (NMPV), was calculated using the peak 
value of the tumor trace normalized by the peak value of the healthy breath hold trace.   
In addition we calculated the correlation coefficient (CC) between the time traces 
observed in the healthy and tumor bearing breasts between the corresponding VOI.    
In addition we tried various other parameters and features, such as time to 
maximum, area under the curve, etc. However, these other features did not show 
promising results, and hence we focused on the 9 parameters just introduced here. 
 
5.8 Conclusion 
 By introducing the DCT filter and the automated program, dynamic DOT data was 
able to be processed quickly and efficiently.  Also, by developing methods to visualize the 
data there has been progress to create check points that assist in breath hold choice and 
quality.  Therefore, the methods explained above has greatly contributed to the quality of 
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the dynamic breath hold time traces.  Last, features were created and calculated to assist 
in the data analysis to determine if the hemodynamic nature of the breath hold can be 
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Chapter 6: Dynamic DOT Results                   | 
6.1. Introduction  
In addition to the static images that we acquired using our DOT system, we had 
acquired and reconstructed movies of the hemodynamics of subjects holding their breath.  
This is the largest dynamic NACT DOT monitoring study at the moment.  Other groups 
differ in imaging modality and methodology, however, few groups have employed 
dynamic techniques for the purpose of observing hemodynamic changes in the NACT 
setting. 
As previously mentioned, given the non-invasive character of optical imaging 
modalities and its sensitivity to blood-dependent parameters and tissue vascularity, 
several groups have evaluated DOT or non-tomographic diffuse optical spectroscopy 
(DOS) for monitoring response to NACT. For example, Ueda et. al. correlated the pCR 
rates to baseline tumor oxygen saturation measurements obtained with a handheld 
spectroscopic measurement system.60  The handheld probe had only one source and one 
detector that were scanned across a region of interest to take both frequency-domain and 
steady-state measurements.  No optical tomographic reconstruction of the entire breast 
was performed. Other groups employed tomographic breast imaging systems.36, 57, 74, 80, 
96 This includes the Zhu group at the University of Connecticut, who performed ultrasound 
guided DOT NACT monitoring studies;58, 72, 73, 78, 79  and Dr. Yodh’s team at UPENN, who 
performed a pilot study in 3 patients undergoing NACT. They employed a combined 
frequency and continuous-wave system that uses two parallel plates to hold one of the 
breasts in place inside a “breast box.” The box is filled with a solution of Intralipid and 
India ink that is used as matching fluid and reference medium.36, 96   These groups have 
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either employed dual-modality OI or DOS to perform NACT monitoring in which 
chromophore concentrations were observed, but have not utilized any dynamic 
capabilities to detect hemodynamic trends of breast tumors. 
In addition to the previous mentioned aspects in Chapter 5, the study differs from 
previous research in a very distinct way. We employ a full-tomographic 3-dimensional 
dynamic DOT imaging that provides information about hemodynamic effects of a breath 
hold in the NACT setting. 
Our group has previously used a dynamic diffuse optical tomographic (DDOT) 
system to observe the hemodynamics of different tumors to determine if a subject had a 
benign or malignant tumor or no tumor at all.  The contrast mechanism that was used for 
that diagnostic study was a simple breath hold.  The quantified hemodynamic time traces 
showed variation between the healthy and tumor bearing breasts of subjects compared 
to those of healthy subjects, which showed similar traces for both breast.  Additionally, 
we observed a more pronounced change in deoxy-hemoglobin (Δ[Hb]%) in the tumor at 
the 15 second post breath hold.23  
Given these promising results, we hypothesized that we will be able to observe the 
vascular changes that occur in tumors utilizing DDOT early in treatment. In particular, we 
expected that information about early changes in the hemodynamics can be used to 
predict the NACT response of individual patients.  To test this hypothesis, we designed a 
longitudinal clinical study that uses DDOT to observe tumor response to throughout 5-
months of NACT.  
 
6.2. Results 
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6.2.1 Patient Summary 
There were forty women recruited and imaged for the study with four subjects 
being excluded due to drop outs or machine malfunctions.  Table 2.2 show a subject 
summary of the patients and their pathological response.   
Since for this chapter we are only concerned with the baseline and week 2 time 
points.  Results from 6 patients were not included in the analysis presented here. One 
patient completely stopped NACT midway through the therapy and was removed from 
the study. For another 2 subjects, instrumentation failure during the imaging session 
resulted in corrupted data sets that could not be used. One subject opted to receive 
radiation therapy in addition to the traditional NACT therapy and therefore was removed 
from the analysis.  Two subjects completely missed there week 2 imaging time point. 
6.2.2 Case Studies 
Before a full statistical analysis is provided, we present two case studies that 
illustrate the overall results we obtained. The first case involves a 46 year-old post-
menopausal woman with a poorly differentiated invasive ductal carcinoma.  Her baseline 
tumor, located in the left breast, had an initial maximum diameter of 2.9 cm as determined 
by mammography (a clinical exam found the diameter to be 5.5 cm).  The patient had a 
pCR to NACT (RCB-0). Figure 6.1A shows the baseline mammogram of her left breast 
with calcifications in the outer quadrants.  Baseline optical images shows a greater 
percent change in [Hb] than in the healthy breast at the 15 second post-breath hold time 
frame (Fig. 6.1B).  Figure 6.1C shows the time traces of changes in deoxyhemoglobin 
(SHb) in response to a breath hold obtained at baseline and 2 weeks after the start of 
NACT. We observe that while the rise slopes of both curves are similar, the washout rate 
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at the two-week time point (black curve) is noticeably higher compares to baseline (red 
curve). 
Figure 6.1 The top row shows imaging results from a patient with a pathological complete 
response (RCB-0); the bottom row shows imaging results from a patient with no response 
(RCB-III) to NACT. Figures A and D display magnetic resonance images (MRIs) obtained 
prior to chemotherapy. Figures B and E are DOT images obtained from the left and right 
breasts just before therapy. The images displayed refer to a time point of 15 seconds 
after the breath hold; Finally, in figures C and F we show time-dependent signal traces in 
response to a 30 second breath hold for the tumor region obtained from DDOT just before 
the start of NACT (baseline) and 2 weeks after treatment initiation.  
 
The second case study involves a 61 year-old post-menopausal woman with a 
moderately differentiated invasive lobular carcinoma.  Employing ultrasound imaging and 
x-ray mammography it was determined that she had a very large tumor of 9.5 cm in 
   100 
 
diameter in the left breast, at the start of the therapy.  She did not respond well to NACT 
and was classified as a RCB-III patient. The patient’s baseline DOT images at the 15 
second post-breath hold time frame show a large enhancement in the left tumor-bearing 
breast, while the healthy breast shows a very small increase in the percent change of 
[Hb] (Figure 6.1E).  Furthermore, there is little difference between the time-trace of SHb 
obtained at baseline and 2-weeks into chemotherapy (Fig. 6.1F). Especially, the washout 
rates are almost the same, which is in stark difference to the time-traces observed in the 
patient with a pCR (Fig. 6.1C). 
6.2.3 Statistical Analysis of Hemodynamic Parameters 
6.2.3.1 Analysis of Hemoglobin Traces observed at Week 2 
We start our analysis by looking at the hemodynamic traces observed 2 weeks 
after the first treatment with taxane. A summary of our main findings is given in Table 6.1. 
The table shows the means values for all four cohorts (RCB-0, I, II, III) for all 9 features 
(IE, PIE, mRise, mFall, τrise, τfall, SPeak, NMPV, and CC) of both the SHb and SHbO2 response 
curves. Furthermore the values for various ANOVA analyses and p-values are given. 
Statistical significant differences are highlighted in green (0.01 ≤ p ≤ 0.05) and yellow (p 
< 0.01). The mrise, Speak, NMPV, and CC do not show any statistically significant difference 
among or between any of the groups for both SHb and SHbO2 traces.  The features that 
show some statistically significant differences between groups are IE, PIE, mfall, τrise, and 
τfall. As these features promise to be good predictors for treatment outcome, we will 
discuss each them in more detail in the following sections. 
 
 




Table 6.1 Summary of features derived from time traces of the hemodynamic responses 
(both SHb and SHbO2) obtained 2 weeks after the initial treatment with taxane. Shown are 
the mean and standard deviation for 9 different hemodynamic-curve features (IE, PIE, 
mrise, mfall, τrise, τfall, Speak, NMPV, and CC) for all four sub-cohorts (RCB 0, I, II, and III).  
One way ANOVA’s were performed among all four groups, then three groups with RCB I 
subjects grouped with either RCB 0 or RCB II subjects.  Fields highlighted in green mark 
statistical significance (p<0.05); yellow denotes “strong” statistical significance (p<0.01), 





RCB 0 RCB I RCB II RCB III 
ANOVA 













pCR vs          
non-
pCR 
(RCB 0  
vs RCB 
I, II & 
III) 
RCB 









SHb 1.02 ± 0.28 0.92 ± 0.04 0.96 ± 0.15 0.71 ± 0.34 0.09 0.04 0.04 0.13 0.15 0.01 
SHbO2 1.03 ± 0.29 0.90 ± 0.03 0.96 ± 0.18 0.73 ± 0.35 0.14 0.08 0.07 0.13 0.17 0.03 
PIE 
SHb -0.89 ± 0.52 -0.51 ± 0.18 -0.40 ± 0.42 -0.30 ± 0.56 0.04 0.02 0.01 0.004 0.01 0.15 
SHbO2 -0.77 ± 0.38 -0.47 ± 0.21 -0.49 ± 0.46 -0.44 ± 0.48 0.30 0.24 0.15 0.052 0.09 0.37 
mrise 
SHb 0.80 ± 0.83 0.47 ± 0.21 0.70 ± 0.49 0.38 ± 0.46 0.58 0.46 0.41 0.34 0.47 0.22 
SHbO2 0.44 ± 0.47 0.24 ± 0.06 0.32 ± 0.20 0.17 ± 0.15 0.39 0.30 0.23 0.14 0.21 0.17 
mfall 
SHb -0.46 ± 0.32 -0.41 ± 0.31 -0.19 ± 0.20 -0.01 ± 0.34 0.015 0.005 0.008 0.01 0.002 0.03 
SHbO2 -0.24 ± 0.25 -0.19 ± 0.13 -0.11 ± 0.12 -0.03 ± 0.14 0.11 0.05 0.054 0.03 0.02 0.09 
τrise 
SHb 0.11 ± 0.06 0.07 ± 0.004 0.17 ± 0.10 0.05 ± 0.04 0.03 0.01 0.04 0.70 0.43 0.03 
SHbO2 0.12 ± 0.06 0.07 ± 0.01 0.17 ± 0.10 0.08 ± 0.06 0.10 0.06 0.17 0.61 0.32 0.13 
τfall 
SHb 0.18 ± 0.09 0.07 ± 0.02 0.09 ± 0.10 0.07 ± 0.07 0.03 0.05 0.01 0.003 0.02 0.16 
SHbO2 0.17 ± 0.14 0.07 ± 0.04 0.11 ± 0.10 0.11 ± 0.07 0.38 0.44 0.23 0.09 0.20 0.59 
Speak 
SHb 9.24 ± 7.54 11.0 ± 5.21 8.61 ± 5.31 9.26 ± 8.31 0.97 0.94 0.99 0.93 0.77 0.95 
SHbO2 5.34 ± 5.29 5.62 ± 1.66 4.34 ± 3.29 3.98 ± 3.82 0.88 0.72 0.78 0.50 0.42 0.63 
NMPV 
SHb 1.83 ± 1.62 1.16 ± 0.85 1.55 ± 1.24 2.93 ± 4.27 0.61 0.43 0.41 0.90 0.72 0.20 
SHbO2 1.85 ± 1.51 0.81 ± 0.26 1.32 ± 0.95 2.57 ± 3.39 0.48 0.39 0.31 0.75 0.97 0.20 
CC 
SHb 0.46 ± 0.38 0.57 ± 0.17 0.36 ± 0.34 0.43 ± 0.36 0.34 0.52 0.96 0.77 0.28 0.93 
SHbO2 0.53 ± 0.37 0.69 ± 0.26 0.41 ± 0.34 0.39 ± 0.37 0.47 0.42 0.69 0.45 0.19 0.50 
 
 Since there are four response groups, there are several ways to create groupings 
of the subjects.  Most studies try to find the patients with a pCR (RCB-0) and group 
patients in classes RCB-I, -II, and -III into one class of non-pCRs.  However, if the goal is 
to find patients who would benefit from a change in therapy, therefore patients that do not 
respond to NACT, one could argue that finding patients that belong to the RCB-III class 
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is equally important. From our statistical analysis, it is apparent that IE and τrise are the 
two best features for finding RCB III subjects. The p-values for differences between RCB-
III and all other patients (last column in Table 6.1) are 0.01 and 0.03 for IE and τrise 
determined for the SHb traces. As seen in Figure 6.2A, subjects that had some response 
to NACT (RCB 0, I, &II) have a higher IE value at week 2 compared to RCB III subjects 
for both the SHb and SHbO2 traces.  Similarly, the responding subjects have a higher τrise, 
but only the SHb traces showed a significant difference between response groups (Figure 
6.2B). 
 
Figure 6.2 Comparison of different groupings for statistically significant features at week 
2.  Week 2 IE value for subject groups responders versus no response (A).  Week 2 PIE 
value for pCR and non-pCR subject groups (B).  Week 2 τrise coefficient for subjects that 
had some response (RCB 0, I, & II) compared to no response subjects with an RCB of III 
(C).  The mfall at week 2 for RCB 0&I and RCB II&III groups (D).  Statistical significance 
between the two response groups is denoted by (*) for p<0.05, (#) for p<0.01, and (&) for 
p<0.001. 
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 If one wanted to identify RCB-II and RCB-III group members as candidates who 
benefit from a change in treatment then the RCB 0&I versus RCB II&III grouping should 
be used (see next to last column in Table 6.1). For this case we observed the largest 
statistical significance (p<0.002) in the mfall for the SHb traces. The RCB 0&I subjects 
showed steeper slopes at week 2 compared to RCB II &III subjects for both the SHb and 
SHbO2 traces. 
 Similar to other studies we also looked for parameters and features for which pCR 
subject could be distinguished best from non-pCR subjects (RCB-0 vs RCB-I, -II, -III).  In 
this case the most significant parameters were PIE (p<0.004) and τfall (p<0.003).  The 
pCR subjects had lower PIE values at week 2 for both the SHb (p<0.004) and SHbO2 
(p<0.052) traces compared to non-pCR subjects (Figure 6.1D).  Also, pCR subjects had 
faster τfall compared to non-pCR subject, but only SHb traces showed statistical 
significance (p<0.03) (Figure 6.3). 
 
Figure 6.3 Week 2 τfall coefficient for subjects that had pCR compared to non-pCR.  There 
is only statistical significance for the SHb parameter with (#) p=0.003 (%d [HBO2]: p=0.08) 
(Left). ROC curve for both SHb and SHbO2 with an area under the curve of 85 and 67, 
correspondingly (Right). 
 
6.2.3.2 ROC Curves for selected Week 2 features 
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Since the difference in mfall for SHb traces between patients with a pCR and non-
pCR produced the strongest statistically significant distinction, we created a ROC curve 
for this case (see Figure 6.3). The sensitivity, specificity, and accuracy for the washout 
rate for SHb was 92.3% (12/13 subjects), 76% (16/21 subjects), and 82.4% (28/34 
subjects), respectively (cut-off point τfall = 0.09). The area under the curve (AUC) was 
0.85, and the PPV calculated to 70.6% with the NPV 94.1%. A similar ROC analysis for 
mfall and PIE for SHb resulted in values shown in Table 6.2.  
As for differentiating the RCB-0&I subjects from RCB-II&III the parameter with 
smallest p-value for this analysis was mfall for SHb.  The corresponding ROC curve has an 
AUC of 0.83 with a sensitivity of 86.7% (13/15 subjects), and specificity of 73.7% (14/19 
subjects), and an accuracy of 79.4% (27/34 subjects).  The PPV was 72.2% and the NPV 
was 85.7%.  Additionally, mfall for SHbO2 was statistically significant (p = 0.02) and the ROC 
analysis can be found in Table 6.2. 
Table 6.2 Summary of binary classification test for the three features that show the 
statistically most significant differences between patients with a pCR (RCB-0) and non-
pCR patients (RCB-I, -II, -II), based on an analysis of the data obtained at week 2.  
Sensitivity is the percent of the pCR subjects that were classified as pCR.  Similarly, 
specificity is the percent of the non-pCR subject that were classified as non-pCR.  
 
pCR v non-pCR Sensitivity Specificity Accuracy AUC PPV NPV 
mfall 92.3%  76.0% 82.4% 0.85 70.6% 94.1% 
PIE 53.8% 90.5% 76.5% 0.73 77.8% 76.0% 
RCB 0&I v. II&III Sensitivity Specificity Accuracy AUC PPV NPV 
mfall for SHb 86.7% 73.7% 79.4% 0.83 72.2% 87.5% 
mfall for SHbO2 86.7%  63.2% 73.5% 0.77 65.0% 85.7% 
RCB 0,I&II v. III Sensitivity Specificity Accuracy AUC PPV NPV 
IE for SHb 96.4% 50.0% 88.2% 0.71 90.0% 75.0% 
IE for SHbO2 96.4% 50.0% 88.2% 0.66 90.0% 75.0% 
τrise for SHb 53.6% 100% 61.8% 0.83 100.0% 31.6% 
 
For differentiation between RCB-III and all other patients, the parameter IE 
determined from the SHb traces produced the smallest p-value (p=0.01).  The 
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corresponding ROC curve has an AUC of 0.71 with an accuracy of 73.5% (30/34 
subjects), sensitivity of 96.4% (27/28 subjects), and specificity of 50.0% (3/6 subjects).   
The PPV is 90.0% and the NPV is 75.0%.  The sensitivity represents the ability to predict 
responding subjects (RCB-0, -I, and –II) from the non-responders.  The sensitivity, 
specificity, accuracy, AUC, PPV, and NPV for the other statistically significant parameters 
can be seen in Table 6.2. 
6.2.4 Analysis of Differences between Baseline and Week 2 Imaging  
In the previous section we only looked at data obtained two weeks after initiation 
of the NACT protocol. To determine if additional parameters and features could be found 
that yield even better separation between various RCB classes, we also analyzed 
differences between data obtained at baseline (week 0) and week 2. Table 6.3 shows a 
summary of each of the features. 
In this table, the most notable entries are the low p-values for Δmfall (changes in 
the fall slope) determined from SHb traces (highlighted in yellow). Of the 6 different 
groupings considered, only RCB-III vs RCB-0, -I, -II, shows a non-significant statistical 
difference (p=0.64). All other groupings show p-values ≤ 0.001. The features Δmrise and 
Δmfall had the lowest p-values for pCR versus non-pCR and can be seen in Figure 6.4.  
All features show an increase for pCR subjects and a decrease for non-pCR subjects.  
For the particularly important subgrouping of pCR versus non-pCR we find that the 
sensitivity, specificity, and accuracy is 61.5% (8/13 subjects), 100% (21/21 subjects), and 
85.3% (29/34 subjects) with an AUC of 0.87.  The PPV was 100% and the NPV was 
80.8%.  The 100% specificity signifies that all the patients with a non-pCR were identified 
as having a non-pCR response. This is of particular importance, as these are exactly the 
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patients that would benefit form a change in therapy. The ROC curves for the significant 
parameters for this grouping can be found in Figure 6.5A&B. 
Table 6.3 Summary of the differences in features between baseline and two weeks after 
the initial treatment with taxane (Week 2 – Baseline). Shown are the mean and standard 
deviation for 9 different hemodynamic-curve features (IE, PIE, mrise, mfall, τrise, τfall, Speak, 
NMPV, and CC) for all four sub-cohorts (RCB 0, I, II, and III).  One way ANOVA’s were 
performed among all four groups, then three groups with RCB I subjects grouped with 
either RCB 0 or RCB II subjects.  Green marks statistical significance (0.01≤p≤0.05).  








RCB I RCB II RCB III 
ANOVA 













pCR vs          
non-
pCR 
(RCB 0  
vs RCB 
I, II & III) 
RCB 0&I  
vs RCB 







SHb 0.03 ± 0.39 -0.39 ± 0.27 -0.04 ± 0.30 -0.29 ± 0.31 0.16 0.28 0.19 0.17 0.47 0.11 
SHbO2 0.16 ± 0.38 -0.35 ± 0.49 0.03 ± 0.41 -0.40 ± 0.37 0.03 0.05 0.02 0.055 0.18 0.01 
ΔPIE 
SHb 0.29 ± 0.66 0.15 ± 0.45 -0.25 ± 0.70 0.02 ± 0.53 0.23 0.12 0.15 0.07 0.06 0.97 
SHbO2 0.17 ± 1.08 0.08 ± 0.77 -0.25 ± 0.54 0.02 ± 0.64 0.63 0.42 0.48 0.28 0.26 0.87 
Δmrise 
SHb 0.47 ± 0.65 -0.06 ± 0.01 -0.13 ± 1.08 -0.07 ± 0.26 0.27 0.20 0.14 0.04 0.07 0.55 
SHbO2 0.26 ± 0.36 0.003 ± 0.001 -0.03 ± 0.51 -0.07 ± 0.14 0.22 0.15 0.11 0.03 0.052 0.34 
Δmfall 
SHb 0.33 ± 0.33 0.03 ± 0.27 -0.38 ± 0.56 -0.13 ± 0.30 0.003 0.001 0.002 0.0004 0.0004 0.64 
SHbO2 0.16 ± 0.21 -0.08 ± 0.31 -0.12 ± 0.27 -0.06 ± 0.13 0.03 0.03 0.01 0.0025 0.01 0.50 
Δτrise 
SHb -0.04 ± 0.14 -0.1 ± 0.21 -0.03 ± 0.19 -0.12 ± 0.22 0.64 0.55 0.60 0.69 0.94 0.31 
SHbO2 0.002 ± 0.10 -0.13 ± 0.20 0.001 ± 0.18 -0.14 ± 0.12 0.15 0.14 0.13 0.32 0.59 0.05 
Δτfall 
SHb 0.02 ± 0.14 -0.01 ± 0.05 -0.11 ± 0.19 -0.07 ± 0.12 0.23 0.11 0.16 0.056 0.04 0.70 
SHbO2 0.01 ± 0.19 -0.01 ± 0.06 -0.14 ± 0.19 -0.06 ± 0.11 0.23 0.11 0.17 0.08 0.055 0.98 
ΔSpeak 
SHb -4.44 ± 4.96 -1.32 ± 1.68 2.13 ± 11.6 -3.53 ± 8.58 0.14 0.16 0.56 0.14 0.16 0.56 
SHbO2 -2.68 ± 3.20 -0.49 ± 2.36 -0.19 ± 6.23 -1.27 ± 4.30 0.20 0.26 0.96 0.20 0.26 0.96 
ΔNMPV 
SHb -0.74 ± 1.83 0.15 ± 0.06 -0.02 ± 1.81 -2.19 ± 4.61 0.37 0.23 0.21 0.93 0.89 0.11 
SHbO2 -0.63 ± 1.86 0.23 ± 0.23 0.41 ± 1.75 -1.92 ±3.67 0.22 0.12 0.11 0.70 0.86 0.08 
ΔCC 
SHb 0.01 ± 0.41 0.07 ± 0.18 0.22 ± 0.45 -0.04 ± 0.38 0.50 0.32 0.33 0.39 0.41 0.41 
SHbO2 -0.02 ± 0.45 0.04 ± 0.27 0.07 ± 0.50 0.02 ± 0.33 0.93 0.92 0.83 0.58 0.73 0.98 
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Figure 6.4 Comparison of pCR and non-pCR for Δmrise (Left), Δmfall (Right), between 
baseline and week 2 imaging.  Statistical significance between the two response groups 
is denoted by (*) for p<0.05, (#) for p<0.01, and (&) for p<0.001.   
 
To separate RCB 0&I subjects from the RCB II&III subjects, τfall  had statistical 
significance for SHb traces in which RCB II&III showed decreases in washout rate and 
pCR subjects had an increase in washout rate.  Figure 6.5C shows the ROC curve for 
Δτfall for SHb.  The AUC was 0.76 and the overall accuracy at the Youden index was 76.5% 
(26/32 subjects).  The corresponding sensitivity, specificity, PPV, and NPV was 73.3% 
(11/15), 78.9% (15/19), 71.3%, and 78.9%. 
To sort out RCB-III patients, the best features seem to be IE and τrise for the SHbO2 
traces (p=0.01, and 0.05, respectively).  The AUC for IE and τrise for the SHbO2 traces was 
0.83 and 0.76 (Figure 6.5D).  Looking at the higher AUC, τrise for the SHbO2 had a 
sensitivity, specificity, and accuracy of 85.7%, 83.3%, and 85.3%, respectively.  Here, the 
sensitivity is the percentage of responders (RCB-0, -I, &-II) that were correctly identified. 
The PPV was 96.0% and a NPV of 55.6%.  
PIE, SPeak, NMVP, and CC did not show any statistical significance between or 
among the different response groups. 
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Figure 6.5 ROC curves for select parameters from Table 6.3 in which the RCB 0 were 
compared to RCB-I, -II, and –III subjects (A and B), the RCB 0&I were compared to RCB-
II&III (C), and last where the RCB-0, -I, and –II were compared to RCB-III subject (D).  
The AUC for Δmrise for SHb and SHbO2 was 0.71 and 0.69, respectively.  For Δmfall the AUC 
for SHb was 0.87 and for SHbO2 was 0.78.  The ROC curve for Δτfall for SHb had an AUC of 
0.76.  The AUC for the Δτrise and ΔIE for SHbO2 was 0.83 and 0.76, correspondingly. 
 
6.3. Discussion 
6.3.1 Summary of Results 
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We have performed a clinical pilot study to evaluate if DDOT can be used to predict 
pathologic response to NACT setting. In this study, 40 patients were enrolled, of which 
dataset from 6 had to be discarded, either because the patients drop out of the study 
before it was finished, or instrumentation malfunction. We evaluated a total of 9 curve 
parameters for time-dependent traces of SHb and SHbO2 recorded inside the tumor.  
Recordings were obtained at baseline, just before treatment initiation (week 0) and 2 
weeks after NACT started. Our study showed that tumors in patients with pCR (RCB = 0) 
have higher washout rates, mfall, by week 2 compared to non-pCR (RCB=I, II, III) patients.  
Using mfall for SHb as parameter to predict patients with a pCR, we achieved a sensitivity 
of 92.3% and a specificity of 76%.  Here sensitivity is defined as the ability to determine 
if the patient will have a pCR, and specificity is how well the non-pCR subjects can be 
determined. Additionally, the Δmrise and Δmfall showed significant difference between pCR 
and non-pCR subjects, where pCR subjects showed an increase in each parameter for 
both SHb and SHbO2 traces.  This may possibly indicate and increase in blood flow in the 
tumor.   For this analysis, the highest AUC (0.87) and specificity (100%) were obtained 
for Δmfall (fall slope) of the SHb trace. 
 In comparing RCB-0/I from RCB-II/III, the best parameter would be mfall at week 2 
for SHb where an accuracy of 79.4%, the highest for this grouping.  However, the best test 
for determining RCB III was using Δτrise for SHbO2 in which the corresponding ROC curve 
had the highest Youden index with a sensitivity of 85.7% and a specificity of 83.3%.   
 IE and PIE show very similar trends to the τrise and τfall parameters. This would be 
expected since these parameters describe similar phenomena.  There also seems to be 
little correlation between the response of the subject and to the absolute values of the 
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traces at any point.  Additionally, since breath hold times between patients varied due to 
the subject’s capability to hold her breath, features such as time to peak was difficult to 
extract.  Therefore, in this current study we focus on the overall shape of the breath hold 
by looking at IE and PIE, as well as, the rise and fall time constants.  
 For this current analysis of dynamic features for NACT tumor response, we 
observed many different features and report here our most promising parameters. 
6.3.2 Physiology Basis of Observed Phenomena 
 Like many other chemotherapeutic drugs, taxanes disrupts the cell cycle to prevent 
proliferation and causes apoptosis. In addition it has been shown that taxanes disrupts 
microvessels and decreases microvascular density.88  However, instead of disrupting 
blood flow, studies in mice have suggested that the diameter of the tumor vessel and 
blood flow velocity inside the vessels actually increase when a tumor responds to 
taxanes.  To explain  this apparent paradox, it has been argued that solid tumors have a 
naturally high interstitial fluid pressure (IFP) due to the compression of blood vessels from 
surrounding tumor cells, the disorganized tumor vascular network, and the absence of 
functional lymphatics.11, 93 Chemotherapy leads to a reduction of tumor cell density, which 
in turn lowers IFP, and consequently increasing blood vessel diameter and blood flow 
velocity. These arguments are supported by another study that demonstrated that IFP 
decreased after breast cancer patients who received the taxane paclitaxel.92  Additionally, 
it was demonstrated that the use of taxanes can help with drug delivery to the rest of the 
tumor by increasing vascular surface area and essentially improving tumor response to 
treatment.93  A Doppler sonography study in which 17 out of 30 patients received 
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paclitaxel based NACT showed an initial increase in vascularity in subjects that 
responded well to treatment followed by a decrease in vascularity.97 
 The results obtained in our study seem to support these findings. For example, we 
observed an absolute increase of mrise, and mfall (Table 6.3, row 3&4, column 3) which 
may be better explained by the cell death that occurs early during treatment, rather than 
anti-angiogenics effects, which would suggest a decrease in blood flow and vascular 
reactivity.  
 
Figure 6.6 The week 0 washout rate ratio (τTumor/ τHealthy) for both SHb and SHbO2 were 
statistically significant different from the value 1 with p <0.01 for each group. 
 
 The tumor region in our dynamic imaging at baseline had a greater washout rate 
compared to that of the contralateral breast (see Figure 6.6). This finding is in 
agreement with other studies, based on color Doppler ultrasound, PET-MRI, and optical 
imaging, in which it was observed that blood flow is greater in tumor regions then in 
corresponding healthy breast tissue.98-101  For example, Choe et. al. used diffuse 
correlation spectroscopy to observe blood flow in breast cancer patients without any 
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treatment.  They observed that blood flow was about twice as fast in tumor regions 
compared to healthy tissue and compared to the contralateral breast.100  Also, we saw 
increases in mrise, mfall, and mfall for pCR subjects between the baseline and week 2 
imaging time point suggesting that there may be increase blood flow in the tumor.  
Therefore, there is evidence in this current study to suggest that the increase apoptosis 
and increase IFP in responding tumors to taxane may cause the increase in mrise, mfall, 
and mfall by the second week of NACT and could be physiologically relevant parameters. 
 
6.4 Conclusions 
We have developed an imaging approach to noninvasively extract information 
about the hemodynamic effects that occur in and around tumors of newly diagnosed 
breast cancer patients. In this study we demonstrate that certain features of the 
hemodynamic responses to a simple breath hold can be used to predict treatment 
outcome in patients undergoing NACT. Using dynamic optics tomographic imaging data 
from 34 patients, we evaluate time-traces of deoxy-hemoglobin concentrations, SHb, and 
oxy-hemoglobin concentration SHbO2 inside the tumor.  Recordings were obtained at 
baseline, just before treatment initiation (week 0), and 2 weeks after treatment started. 
Our study showed that tumors in patients with pCR (RCB-0) have statistically significant 
higher washout rates, mfall, at week 2 compared to non-pCR (RCB-I,-II, III).  Using τfall for 
SHb as parameter to predict patients with a pCR, we achieved a sensitivity of 92.3% and 
a specificity of 76%.  Additionally, the difference in rise slope, mrise, and fall slope, mfall, 
between the two imaging points showed significant difference between pCR and non-
pCR subjects, where pCR subjects showed an increase in each parameter for both SHb 
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and SHbO2 traces. Finally, we determined that IE and τrise of the SHb traces are the two best 
features for comparing RCB-0/I/II vs. RCB III patients, i.e. the patients at highest risk for 
breast cancer. We were able to get 100% specificity for τrise of the SHb traces when looking 
at RCB-0, I, &–II versus RCB-III, which indicates that we can identify all non-responders. 
These are subjects that are least likely to respond NACT and hence may be prime 
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Chapter 7: Combined Analysis             . 
7.1 Introduction 
There have been several optical and non-optical imaging studies that have 
observed changes of breast tumors during or after NACT.   Since few patients have a 
pCR after treatment, the purpose of the studies was to identify the subjects who do not 
have a good response to treatment early during NACT. Then other options for treatment 
could be considered instead of continuing with a treatment that yields no result.  
Therefore, more personalized treatments could be developed to optimize the patient 
outcome of those who do not respond. 3, 48   
In Chapter 1, I go into more detail about monitoring using traditional methods.  
Briefly, in a meta-analysis using CE, MG, US, and MRI, that had an accuracy of 57%, 
74%, 79%, 84%, respectively.53  Additionally, some of these methods are not feasible for 
monitor, such as MG or MRI.  MG would be dangerous for multiple imaging session due 
to radiation.  MRI would not be feasible since it would be too expensive for multiple 
imaging sessions.  Since traditional method lack the accuracy or the feasibility for tumor 
monitoring or predicting response, DOT has emerged as a novel imaging modality for 
tumor monitoring. DOT uses optical transmission measurements with non-ionizing, low-
intensity near-infrared light to generate three-dimensional maps of various tissue 
parameters.  
There are several advantages to using optical imaging (OI) to monitor breast tumor 
response over conventional imaging techniques.  For example, OI uses non-ionizing light 
sources that allow for multiple imaging session within a short period of time.  Therefore, 
measurements can be taken a few weeks to a few days apart from each other with no 
   115 
 
adverse effect.  OI is also sensitive to parameters that change over the course of 
treatment, such as tissue vascularity or hypoxia.3, 48   
Several studies have shown that there is a change in optical properties over time 
during the course of neoadjuvant chemotherapy. 48, 57-60  Ueda et. al. used discriminant 
analysis to predict tumor response at the baseline with a sensitivity of 100% and 
specificity of 85.7% when combining the estrogen receptor status with baseline SO2%.  
Otherwise, with just using SO2% at baseline imaging there was a sensitivity of 75% and 
a specificity of 73.3%. The subjects of the study received four different treatments, some 
concurrent with bevacizumab and trastuzumab.60   
 Zhu et. al. found that by adding optical imaging parameters of [HbO2]and [HbT] to 
their logistic regression model, there was a significant improvement to sensitivity and 
specificity for the pre-treatment time point.  Using pathological variables alone they saw 
an average sensitivity of 56.8% and specificity of 88.9%.  By adding [HbT] the sensitivity 
and specificity were 79%, and 94%, respectively.  Also, by adding [HbO2] to the model, 
the sensitivity became 77% and specificity was 85%.  Using just the training set of data, 
they were able to increase the AUC by adding the [HbT] for each cycle of chemotherapy 
to the model, so that by just using the pathological variables the area under the curve was 
87.9%, but combining the pathological variables with baseline [HbT], and cycle 1-3 
measurements the AUC was 100%.78 These analyses are based on data collected from 
32 patients that received four different treatments with three patients receiving 
bevacizumab.58 
 Falou et. al. observed 15 patients that received several different treatments 
including chemoradiotherapy and was able to determine a 100% sensitivity and 83% 
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specificity with [Hb] and 75% sensitivity and 100% specificity with water percentage one 
week after the beginning of NACT.  They employed univariate methods without cross 
validation.86 
In the previous chapters, we looked at 3D images (static data) and 3D movies 
(dynamic data) individually to determine if the response of a subject could be predicted 
using these DOT techniques.  Both studies track the tumor progression in 34 breast 
cancer patients receiving the same NACT regimen.  The static DOT study observed how 
concentrations of oxy-hemoglobin, deoxy-hemoglobin, water fraction, total hemoglobin, 
and oxygen saturation changed over the entire course of treatment at six imaging time 
points and how normalized oxy-hemoglobin correlated significantly with the residual 
cancer burden throughout NACT.  Our dynamic DOT study selected features from the 
hemodynamic trend that occurs as a subject held their breath and that could be used to 
determine the pathological response two weeks after the beginning of NACT.  However, 
an in depth discriminant analysis of the features acquired had not been done, which is 
the focus of this chapter. 
 For the current study we employ discriminant analysis techniques and use baseline 
biomarkers, static DOT imaging features, and dynamic DOT imaging features to improve 
the accuracy, sensitivity, and specificity of our tumor prediction models.  We have looked 
at models that separate the pCR subjects from the non-pCR subjects.  Ideally, the poorly 
responding subjects (RCB-III) are a population of great concern, but the current number 
of subjects that fall into this group is 6.  Therefore, discriminant analysis with this small 
number would be difficult to interpret.  Also, since the goal of the study is to determine 
early on within treatment whether or not NACT is effective, we have concentrated our 
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feature selection to the first two imaging time points: baseline and week 2 (third cycle of 
taxane).  Here we show that the combination of static and dynamic features yields the 
highest accuracy and out performs baseline biomarker analyses. 
 
7.2 Methods 
7.2.1 Patient population 
 There were 40 women with breast cancer imaged with four exclusions.  Here, we 
only look at the first two time points (baseline, week 2) since the largest advantage for the 
patient would to be able to determine early within treatment the tumor response.  A more 
detailed description of the subject population can be found in Table 2.3.  
7.2.1 Pathological, Static, and Dynamic Parameters 
 There were five data sets we incorporated for the current study: pathology, 
baseline static data, week 2 static data, baseline dynamic data, and week 2 dynamic data.  
These data were obtained from the results of the previous chapters.  For the pathological 
biomarkers, the estrogen receptor status (ER), progestogen status (PR), and Ki-67 
protein percentage (Ki67) were acquired before the initiation of NACT.  Four patients were 
missing their baseline Ki67 tests due to outside diagnosis and testing.  The static DOT 
parameters include concentration of [HbO2], [Hb], WF, [HbT], SO2%, and the normalized 
concentrations by both the healthy breast (T/H) and the non-tumor region in the tumor 
bearing breast (T/nT).  Only week 2 features have the percent change from baseline 
imaging.  Additionally, the percent change from the baseline was found for the normalized 
values as well.  These parameters are described in more detail in chapter 5.  The dynamic 
parameters are taken from the hemodynamic time traces of the percent change in [HbO2] 
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(SHbO2) and [Hb] (SHb) during a breath hold.  Some of the features include the rise slope, 
fall slope, rise rate, washout rate and maximum peak value. The calculations and 
descriptions of the dynamic features can be seen in chapter 4. A list of all parameters are 
shown in Table 7.1. 
Table 7.1 Summary of features where X could be any of the features above and Y is any 
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7.2.2 Discriminant Analysis 
 Discriminant analysis was performed using MatLab.  Both univariate and 
multivariate methods were employed for calculating the accuracy, sensitivity, specificity, 
positive predictive value (PPV), and negative predictive value (NPV) for determining 
whether the patient had a pCR or non-pCR to treatment.  Sensitivity in this study 
represents the probability that a positive predicted condition is a true pCR.  Conversely, 
specificity represents the probability that a negative predicted condition is a true non-pCR. 
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The data was divided into testing and training data where 25% of the data was 
used for testing.  The univariate and multivariate discriminant analysis was repeated 20 
times with a different random portion of the data removed for testing. Then the mean and 
standard deviation were calculated for the accuracy, sensitivity, specificity, PPV, and 
NPV.
For the univariate method, the cutoff point/threshold for was taken at the Youden 
index (YI) of the training data and then applied to the testing data.  As for the multivariate 
method both linear discriminant analysis (LDA) and quadratic discriminant analysis (QDA) 
were employed.  These methods were used for the baseline and week 2 time points, and 
the static and dynamic data.  Last, the static and dynamic features were both used for 
LDA and QDA.   
The feature for the univariate analysis with the largest YI are was reported.  For 
the multivariate method, LDA and QDA were performed for every combination of features 
between two sets of data and the combination with the highest YI was reported. 
 
7.3 Results 
7.3.1 Univariate Analysis 
 First, we looked at the ROC curves of the just the pathological baseline biomarkers 
to determine the standard ROC that the physicians would have for this particular study.  
Figure 7.1 shows the ROC curves for ER, PR, and Ki67 that have an area under the curve 
(AUC) of 0.89, 0.85, and 0.53, respectively.  
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Figure 7.1 ROC curves of pathologic biomarkers ER, PR, and Ki67. 
ER has the highest AUC with a sensitivity of 85.7%, a specificity of 81.8%, and an 
accuracy of 83.3%.  The sensitivity analysis at the YI for the biomarkers can be seen in 
Table 7.2.  Additionally, these pathological biomarkers underwent univariate analysis with 
cross validation (Table 7.3).   
Table 7.2 Sensitivity analysis of ROC curves in Figure 7.1 for ER, PR, and Ki67. 
Biomarker AUC Sensitivity Specificity Accuracy PPV NPV 
ER 0.89 85.71% 81.82% 83.3% 75.0% 90.0% 
PR 0.85 85.71% 77.27% 80.6% 70.6% 89.5% 
Ki67 (n=32) 0.53 90.91% 42.86% 59.4% 45.5% 90.0% 
 
 First, univariate analysis was performed to see if a single variable would be viable 
enough for tumor response prediction at the first two imaging time points during NACT.  
Table 7.3 shows the features for each set of data that had the highest Youden index.  Out 
of the data sets shown, pathology had the highest YI by using the ER percentage.  
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Consequently, ER had the highest accuracy (72.8%) and sensitivity (64.2%).  However, 
the sensitivity and accuracy for any of these parameters is <75%.  Therefore, multivariate 
analysis was performed to see if the accuracy, sensitivity, and specificity could be 
increase. 
 
Table 7.3 Summary of univariate analysis for each data set with the feature with the 
greatest Youden index. 
Data Set Feature Accuracy Sensitivity Specificity PPV NPV 
Pathology ER 72.8%±11.7% 64.2%±14.6% 89.6%±14.8% 91.4%±12.5% 56.9%±17.4% 
Static Baseline [Hb] 46.1%±15.4% 25.0%±44.4% 75.0%±44.4% 51.1%±14.9% 44.4%±15.7% 
Static Week 2 %Δ[HbO2](T/nT) 71.3%±11.9% 53.3%±20.7% 96.6%±8.2% 95.3%±12.6% 61.2%±14.7% 
Dynamic Baseline τRise for SHbO2 50.0%±13.7% 21.8%±12.8% 96.5%±9.0% 88.9%±27.4% 43.2%±15.2% 
Dynamic Week 2 PIE for SHb 70.0%±14.5% 62.3%±22.1% 85.5%±14.2% 87.0%±12.5% 61.2%±22.2% 
 
 
   
Figure 7.2 ROC curves of best DOT features from univariate analysis. 
 
 Figure 7.2 shows ROC curves for the best DOT features from the univariate 
analysis.  Here the highest area under the curve is the week 2 static feature of 
   122 
 
%Δ[HbO2](T/nT).  This features has a sensitivity of 76.9% and specificity of 90.5% (see 
Table 7.4).  Additionally, %Δ[HbO2](T/nT) has the highest accuracy of the features (85.5%), 
which is higher than the ER ROC analysis.  However, %Δ[HbO2](T/nT) has a lower 
sensitivity than ER. 
Table 7.4 Summary of sensitivity analysis of the best select features from the univariate 
analysis seen in Table 7.3 
Feature AUC Sensitivity Specificity Accuracy PPV NPV 
Baseline Static:[Hb] 0.56 64.3% 72.7% 69.4% 60.0% 76.2% 
Week 2 Static: 
%Δ[HbO2](T/nT) 
0.87 76.9% 90.5% 85.5% 83.3% 86.4% 
Baseline Dynamic: 
τRise for SHbO2 
0.54 21.4% 100.0% 69.4% 100.0% 66.7% 
Week 2 Dynamic: 
PIE for SHb 
0.79 92.3% 61.9% 73.5% 60.0% 92.9% 
 
7.3.2 Multivariate Analysis 
 
Table 7.5 Summary of LDA and QDA for each data set with the features with the greatest 
Youden index. 
Data Set Type Feature I Feature II Accuracy Sensitivity Specificity PPV NPV 
Pathology 
LDA ER PR 72.8%±15.5% 80.0%±20.3% 68.7%±18.2% 62.7%±23.2% 83.7%±14.6% 
QDA ER PR 75.0%±21.3% 78.3%±37.5% 57.5%±43.8% 72.5%±25.0% 82.3%±35.2% 
Static Baseline 
LDA [HbT](T/nT) [HbO2](T/H) 70.6%±14.1% 43.4%±30.5% 89.1%±19.5% 79.6%±32.1% 72.6%±14.5% 
QDA [Hb](T/nT) [HbT](T/H) 67.8%±17.6% 42.8%±21.2% 87.7%±18.8% 77.6%±33.1% 64.4%±20.6% 
Static Week 2 
LDA SO2%(T/nT) %Δ[HbO2](T/H) 82.5%±16.4% 80.8%±28.2% 85.5%±18.4% 73.7%±33.2% 90.3%±14.5% 
QDA %ΔSO2% %ΔWF(T/nT) 81.3%±11.1% 84.4%±22.5% 83.7%±15.5% 72.3%±24.7% 90.0%±13.7% 
Dynamic Baseline 
LDA Fs SHb NMPV for SHb 65.6%±16.5% 48.4%±27.0% 83.6%±19.7% 72.1%±27.8% 68.1%±19.3% 
QDA Fs for SHb τRise for SHb 78.3%±14.2% 92.7%±19.7% 70.2%±23.3% 73.1%±21.5% 93.3%±16.7% 
Dynamic 
Week 2 
LDA ΔFs SHb PIE for SHb 88.8%±13.4% 81.3%±28.5% 92.1%±12.4% 82.1%±29.4% 91.7%±11.5% 
QDA τFall for  SHb ΔSPeak for SHbO2 88.1%±7.6% 89.0%±16.3% 87.9%±10.4% 82.6%±15.9% 93.0%±10.0% 
  
 In Table 7.5 is a summary the features that had the highest YI of the discriminant 
analysis for each data set using both LDA and QDA.  The QDA for dynamic week 2 data 
has the highest YI, where accuracy is 88.1%, sensitivity is 89.0%, specificity is 87.9%, 
PPV is 82.6%, and NPV is 93.0%.  However, the LDA for dynamic week 2 had a higher 
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accuracy (88.8%). Both the static and dynamic week 2 data set had the highest 
accuracies (>80%) among the analyzed data sets.   
 The best performing test for the baseline data sets was the dynamic data set with 
QDA where the accuracy was 78.3%, the sensitivity was 92.7% (the largest sensitivity 
from Table 7.5), and a specificity of 70.2% .   
This is a large increase in accuracy compared to the univariate analysis.  LDA and 
QDA yield similar results for each of the data sets, in which QDA only occasionally 
increases accuracy or the YI.   
7.3.3 Multivariate Analysis with Pathology 
 
Table 7.6 Summary of LDA and QDA for pathology combined with DOT features. 
Data Set Type Pathology Feature DOT Feature Accuracy Sensitivity Specificity PPV NPV 
Static Baseline 
LDA ER SO2% 75.6%±15.1% 81.9%±24.8% 75.8%±15.0% 68.2%±19.5% 84.7%±18.7% 
QDA ER [HbT] 75.6%±17.1% 82.0%±21.1% 75.9%±23.8% 68.0%±26.6% 86.8%±16.4% 
Static Week 2 
LDA PR %Δ[HbO2] 85.0%±11.2% 86.8%±25.2% 83.9%±14.0% 75.5%±19.3% 92.9%±12.1% 
QDA ER %Δ[HbT](T/H) 85.0%±10.4% 80.3%±18.0% 88.2%±15.3% 82.9%±21.0% 88.2%±10.2% 
Dynamic Baseline 
LDA PR mFall for Hb 82.2%±12.2% 86.3%±18.8% 82.0%±18.7% 76.7%±22.7% 90.1%±14.4% 
QDA ER IE for Hb 78.9%±12.4% 85.6%±17.4% 76.3%±18.9% 73.7%±21.2% 86.5%±15.7% 
Dynamic 
Week 2 
LDA ER ΔmFall for Hb 85.6%±11.7% 81.5%±22.2% 90.5%±12.6% 85.8%±18.8% 87.5%±16.7% 
QDA PR %ΔτFall for Hb 84.4%±9.0% 76.3%±24.1% 91.6%±11.1% 86.7%±17.4% 86.0%±12.4% 
 
 Since there was still room for improvement for the YI and accuracy, we combined 
each of the DOT parameters with the pathology of the subject.  Table 7.6 shows the 
combination of features with the highest YI for each data set.  The best performing test 
was the LDA of pathology combined with dynamic week 2.  This combination has an 
accuracy of 85.6% with a sensitivity and specificity of 81.5% and 90.5%, respectively.  
The next best performing test is the QDA for the combination of pathology features and 
static week 2 features, where the accuracy, sensitivity, and specificity are 85.0%, 80.3%, 
and 88.2%, correspondingly.  The best performing pathology and baseline data set 
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combination was LDA for dynamic week 2 with an accuracy of 82.2%, sensitivity of 86.3%, 
and specificity of 82.0%.   
 The top results from the multivariate analysis are an improvement from the 
univariate analysis of the pathology. 
 
7.3.4 Combining Baseline and Week 2 features 
 
Table 7.7 Summary of LDA and QDA for baseline versus week 2 features. 
 Type Baseline Feature Week 2 Feature Accuracy Sensitivity Specificity PPV NPV 
Static 
LDA WF(T/H) %Δ[HbT](T/nT) 81.3%±13.1% 81.7%±23.5% 84.2%±13.4% 73.8%±22.6% 87.7%±15.4% 
QDA [Hb](T/H) [HbT] 75.0%±18.6% 82.0%±31.6% 75.5%±20.4% 65.1%±28.5% 87.5%±20.8% 
Dynamic 
LDA NMPV  for SHbO2 ΔmFall for  SHb 86.3%±10.7% 76.3%±32.0% 90.7%±11.1% 77.2%±29.9% 90.4%±11.4% 
QDA mFall for SHb τFall for SHb 83.1%±10.2% 81.7%±22.1% 85.5%±11.3% 71.9%±22.1% 89.0%±14.4% 
 
 In order to see if the static or dynamic data sets could be used individually, LDA 
and QDA were used to combine baseline a week 2 features.  The highest YI index was 
the dynamic QDA test where the accuracy was 83.1%, sensitivity was 81.7%, and 
specificity was 85.5% using the Fs for SHb and τFall for SHb as the features.     However, 
the highest accuracy and specificity was from the dynamic LDA test (accuracy 86.3%, 
specificity 90.7%).   
 Besides the baseline parameters, this analysis does not yield higher accuracies or 
YI from the multivariate analysis using only one data set at a time.   
7.3.5 Combining Static and Dynamic features 
 
Table 7.8 Summary of LDA and QDA for static versus dynamic features. 
 Type Static Dynamic Accuracy Sensitivity Specificity PPV NPV 
Baseline 
LDA [HbO2](T/H) NMPV for SHbO2 63.3%±17.3% 39.9%±34.5% 83.5%±17.7% 55.2%±35.3% 71.2%±20.5% 
QDA SO2%(T/nT) Fs for SHb 67.2%±13.2% 54.0%±27.7% 82.1%±21.4% 73.3%±24.3% 71.5%±19.5% 
Week 2 
LDA %Δ[HbO2](T/H) τFall for SHb 91.3%±10.8% 89.7%±15.6% 95.0%±11.3% 91.7%±19.3% 92.0%±11.6% 
QDA %Δ[HbO2] τFall for SHb 93.1%±8.6% 87.1%±25.4% 94.4%±10.5% 90.6%±17.4% 94.8%±9.9% 
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The static and dynamic parameters were combined and the test with the highest 
YI was LDA for week 2, but the highest accuracy was QDA for week 2.  The LDA for week 
2 had an accuracy of 91.3%, a sensitivity of 89.7%, and a specificity of 95.0%.  Also, the 
week 2 LDA test had a PPV of 91.7% and a NPV of 92.0%.  As for the QDA, there was 
an accuracy of 93.1%, which is the highest accuracy out of all the previous discriminant 
analyses.  The combination of data sets can be seen in Figure 7.3, where a non-validated 
QDA was performed.  Here the accuracy, sensitivity, specificity, PPV, and NPV were 
94.1%, 92.3%, 95.2%, 92.3%, and 95.2%, respectively.   
 
Figure 7.3 QDA without validation of the week 2 features from the static and dynamic 
data sets.  The accuracy, sensitivity, specificity, PPV, and NPV were 94.1%, 92.3%, 




The univariate analysis showed that the pathology had the best YI, but was not 
clinically useful.  Yet, the analysis gave us a standard in which we needed to exceed in 
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which ER status had a sensitivity of 64.2% and a specificity of 89.6%.  The multivariate 
analysis for both week 2 static and dynamic data sets performed much better than the 
univariate analysis.  The week 2 data sets had accuracies that were all over >80%.  From 
the baseline data sets the dynamic QDA had the highest YI and sensitivity (92.7%), which 
may be helpful at determining pCR at the baseline imaging.  However, the multivariate 
analysis was most accurate when the week 2 data was taken into consideration. 
The best baseline testing was the combination of pathology and dynamic features, 
which yielded an accuracy of 82.2% for LDA (see Table 7.6).  Here, since the accuracy, 
sensitivity, specificity, PPV, and NPV are all >75.0%, this test may be viable for baseline 
screening of NACT effectiveness before the first dose is administered.  However, the 
analysis clearly shows that the week 2 time point yields better testing options that give 
higher accuracies, sensitivities, etc.  The best week 2 performing combination would be 
between the static and dynamic features, where an accuracy of 91.3% was acquired from 
LDA, and an accuracy of 93.1% was acquired from QDA.  Therefore, the QDA model may 
be used tumor response prediction (see Figure 7.3).  Future studies could consist of using 
this model to determine which patients will not have a pCR and possibly add or change 
the agents used from their current treatment protocol. 
The physiological features that yielded the highest accuracy from our discriminant 
analysis test were %Δ[HbO2] and the washout rate τFall at the week 2 time point.  The 
physiological basis of each of these parameters has been explained before in sections 
5.4 and 6.4 of this thesis.  Briefly, there is a tendency for pCR subjects to have a decrease 
in [HbO2] levels by the second week of NACT initiation.  Also, we have observed that pCR 
subjects have a higher washout rate by week 2 compared to non-pCR subjects.  As a 
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result, the pCR subjects tend to cluster in the top left portion of the graph that compares 
these two features (see Figure 2).  While the non-pCR subjects tend to have little change 
or an increase in [HbO2] levels, as well as, a slower washout rate at the week 2 time point.  
Therefore, the combination of the features yields a very good prediction model for tumor 
response to NACT. 
The result with the highest YI was the LDA with the week 2 static and dynamic 
data combined.  With an accuracy of 91.3%, a sensitivity of 89.7%, and a specificity of 
95.0%, our model outperformed the traditional methods seen in Table 1.6.  Even MRI, 
which had the accuracy of 84% was still lower than the current results we have obtained.  
Therefore, using dynamic and static information can plausibly predict tumor response to 
NACT treatment. 
Overall, the discriminant analysis for pathology, static features, and dynamic 
features have yielded promising results that could potentially be used in interventional 
studies to improve the outcome of the patient, based on their DOT imaging.  Especially, 
combining the static and dynamic capabilities of our imaging system to obtain different 
features to use in simple discriminant analysis techniques has acquired a prediction 
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Chapter 8                      . 
8.1 Summary 
Our current DOT breast imager is capable of dual breast dynamic and static 
imaging.  Therefore, there is a vast array of information we can utilize to observe tumor 
vascular changes.  The static images are capable of locating the tumor position, as well 
as showing changes over treatment that correspond to the pathological response of the 
patient. Additionally there are visible changes in the dynamic traces of the patient breath 
hold that also can be analyzed to determine if the subject has a good response.  The 
combination of this information has been utilized to further assist in determining response.  
Ultimately the goal was to use the week 2 information to predict whether early in the 
treatment if there is a response and change the treatment plan accordingly to optimize 
the patients’ outcomes. 
There were 40 subjects have been recruited for this current study with 36 subjects 
that have been used for the overall analysis of this NACT monitoring study. The number 
of patients in our study that have a pCR was about 38.9%, which corresponds to similar 
numbers in the literature.1, 3 Our analysis has shown promising results, with significant 
difference in percent change of [HbT] at the week 2 time point.  Our results correspond 
with previous studies where pCR patients show a drop in [HbT] after the first few weeks 
of treatment.   However, in other studies, subjects received different chemotherapy 
regimens or have taken additional cancer drugs.10-12, 15-20  Here, we look at subjects that 
have all undergone the same treatment, throughout the length of their therapy. 
The static images with different chromophore concentrations that were observed 
indicate that the baseline and week 2 time points were the most opportune chance for 
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determining a pCR or not to treatment.  We also observed that baseline [HbO2](T/H) 
significantly correlates with RCB score.  Additionally, several parameters for week 2 
showed significant correlations.  When the percent change from the baseline was 
calculated, %Δ[HbO2](T/nT) show significant correlation throughout each of the imaging 
time points with the RCB score. 
The hemodynamic effects visualized in this study were acquired by using non-
invasive methods to understand the vasculature of healthy and diseased tissue.  Our 
analysis shows how the hemodynamics of breast cancer changes as a patient receives 
treatment over two weeks.  This information could be beneficial to physicians as a method 
of tumor monitoring and treatment evaluation.  For pCR subjects, we observed that there 
is an increase in the washout rate, fall slope, and rise rate by the second imaging time 
point.  The possible physiological reason could be the increase in apoptosis which 
decreases IFP and allows an increase of blood flow. 
Last by combining the static and dynamic data sets and performing simple 
discriminant analysis methods, we were able to obtain an accuracy as high as 93.1% at 
determine pCR subjects from non-pCR subjects. 
 
8.2 Future Work 
8.2.1 Hardware Development 
There are several possible modifications to the current imaging system that could 
be made to increase the accuracy and quality of the images and the overall amount of 
information acquired.  There could be the addition of wavelengths that could assist with 
image reconstructions to better visualize chromophore concentrations, such as lipid.  
   130 
 
Also, there could be a frequency domain (FD) component added to increase the accuracy 
of the scattering coefficient and the overall reconstruction image.  Last, the patient 
interface could undergo minor modification to help to ensure contact. 
Currently, lipid cannot be reconstructed using the current wavelengths that the 
system has.  While, important chromophores such as oxy and deoxy-hemoglobin can still 
be visualized, adding another feature to the analysis could help determine the response 
of the subject over the course of treatment.  Additionally, having more laser wavelengths 
than chromophores could increase the accuracy of the reconstruction algorithm by 
decreasing the ill-posedness of the solution.102 
Since the breast imager is a continuous wave system, there is no phase 
component recorded.  The phase component of the signal usually helps distinguish 
between the absorption and scattering coefficient102.   A FD component could be added 
in order to get a baseline image of the subject.  Then the system could be switched to 
CW mode and continue with the dynamic imaging.32, 35, 36  Then the baseline FD 
measurement can be used to determine the initial scattering coefficient and could be used 
for the static measurements. 
For the patient interface, there could be pressure sensors setup along the rings of 
the interface.  These pressure sensors could be coupled with the computer and give a 
binary signal in which it indicates good or bad contact with the detector fibers.  
Occasionally, proper contact with the patient interface is hard to determine.  The pressure 
sensors could take out some of the guess work for optimal patient positioning and 
increase the quality of the image, since (as shown in chapter 3) poor contact leads to 
artifacts in the image. 
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8.2.2. Static Imaging Improvements 
 The current static reference poses some logistical problems.  The liquid phantoms 
only last about a month before they are no longer useful.  The intralipid for these 
phantoms are also relatively expensive and could cost about $80 per phantom. Solid 
phantoms would be more cost effective.  The upfront cost (~$3,000) would be relatively 
expensive, but would pay for its self over time, since it would not need to be replaced.  
The solid phantom could be shaped to each of the rings of the patient interface, which 
would prevent any contact issues with the detectors.  Also, there would be no variability 
between phantoms since the same one would be used for all imaging.  Additionally, the 
solid phantoms would be key in multi-center studies in order to remove the variability of 
liquid phantom preparation by different groups.  Therefore, with solid phantoms, the 
accuracy of the static images could increase and possible artifacts could be avoided. 
8.2.3 Dynamic Imaging 
 One issue that the dynamic portion of the study has run into is knowing when a 
patient holding their breath.  We depend on the honesty of the patient to tell us when they 
begin breathing again, but sometimes it is apparent that the patient is not holding her 
breath.  Also, when they begin or end the breath hold is up to them and we cannot always 
observe these timings.  To fix this issue, there may be two possibilities: have the patient 
breath in different gasses or have the patient wear a strain gage that tracks their 
breathing. 
 There has been a study where the patient breathes in a different combination of 
gasses and the tumor can be distinguished.103  This would be one way of controlling the 
experiment and making sure that each patient underwent the same protocol.  With the 
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breath hold method, each patient holds their breath for a different length of time, but there 
would be more control over the timing with the inhalation of timed gasses.  However, this 
does introduce and extrinsic element that patients may not appreciate. 
 Also, there is a simple strain gage device that can be placed around the chest 
(below the breasts) that can measure the expansion and relaxation of the muscles around 
the lungs.  The strain gage device can provide a signal to the computer and recorded in 
tandem with the optical imaging.  Hence, the breathing of the patient and the optical 
imaging data could be digitally match up and possibly automatically segmented to show 
just the breath hold data.  This is a simple solution that would not add an extrinsic factor 
to the patient, such as the different gasses.  However, the downside would be that the 
breath hold times could still range from subject to subject. 
8.2.4 Patient comfort 
 Patient comfort is often neglected in scientific articles, but I feel that it is somewhat 
worth mentioning since the system was designed to allow the patient to be as comfortable 
as possible.  Our current system and study can provide a comfortable and fairly quick 
means of imaging patients with breast cancer.  There is no need for painful compression 
that is required by mammography.  Also, the actual imaging takes about 10-12 minutes 
(maybe 20 minutes with setup time), which would be much quicker than a patient would 
experience in a MRI system.  Additionally, when we examine the hemodynamic 
phenomena caused by the tumor vasculature, we look at intrinsic contrasts that occur 
during a simple breath hold so there is no need for injections of contrast agents.   
I believe these factors have had a large impact on our capability to maintain 
constant accrual of patients on the study and to have them return for all or most their 
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imaging sessions.  However, there are still improvements that can be made to ensure the 
comfort of the patient.  First, one of the biggest complaints I get about the system is that 
the patient’s back or neck will hurt from the hunch over position that they are in.  There 
was even a point in the study where we stopped using a chair and had the patients stand 
throughout the imaging since they were uncomfortable and there was a lack of space in 
the new imaging room.  However, this problem is still occurring, especially when the 
patient already had a preexisting condition that involves shoulder or back pain.  This 
problem could be eradicated with a system that was set up like a bed.  A bed interface 
would be more comfortable, could possible lead to better contact with the patient 
interface, and lead to less motion from the patient who may adjust themselves during 
imaging to be more comfortable.  
8.2.5 Imager Software Development 
Currently, the DDOT breast imager has a LabView GUI that controls the system.  
This system is difficult to navigate.  An engineer that has been trained in LabView can 
use the DDOT GUI interface.  However, for a research coordinator, clinician, or physician 
the interface could be confusing and takes a while to train a single person on how the 
program works.  Therefore, to increase the ease of use of the system the GUI should be 
rearranged.  The best way might be to have a series of windows that prompt the user to 
enter the necessary information.  For example, at the beginning the program, it prompts 
the user to enter the number of sources and detectors for the subject.  Afterwards, the 
program could ask if the patient is in position and then automatically configure the gain 
bits.  Then the subject information could be entered and then automatically begin imaging.  
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Overall, a more user friendly interface is needed in order to increase personnel that can 
operate the system.  For multi-center studies this would be essential. 
8.2.5.1 Pre-processing and Post-processing 
 The short comings of some of the pre- and post-processing techniques have been 
explained in previous chapters.  Yet, I would like to mention that there are still work to be 
done with this regard.  Overall, these pre- and post-processing tools could be placed into 
a single MatLab program or GUI for both the dynamic and static data, which would 
increase the ease of use and decrease the time spent on processing. 
8.2.5.2 Real-Time Imaging 
A key facet and long term goal of DOT imaging would to obtain real time images.  
The current set up lets us take the data a reconstruct the images over a day.  However, 
with most imaging systems such as US, imaging can be viewed in real time.  The limiting 
factor for DOT are the reconstruction algorithms.  Our current study reconstructs 3D 
images and custom designed meshes.   However, fast 2D images may be possible to 
procure.  Since the rings of the breast imager are fixed, the mesh for each ring will always 
remain the same.  Hence, 2D meshes could be generated once and used for real-time 
reconstruction.  Also, 2D reconstructions are much faster than 3D reconstructions since 
there are many less units of space needed to solve the inverse problem.  Additionally, to 
increase the speed the first three or four iterations could be used as the final image 
(instead of waiting for 9-10 iterations).  As result, we could get images within minutes 
instead of hours for a single imaging.  Later, full tomographic images could be created in 
order to increase the accuracy and understanding of the data (tumor location, 
hemodynamic effects, etc.).  The real-time imaging could aid in quick diagnosis and tumor 
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response predictions that could help the physician and patient move forward with 
treatment. 
8.2.6 Interventional Studies 
 By using the current data set and developing a model for discriminating the 
response groups at the baseline or early treatment time point such as the second week, 
interventional studies could be developed.  The interventional study could consist of 
baseline imaging and initial assessment.  We have develop discriminant analysis models 
that can have a sensitivity as high as 94.1% at determining a pCR.  Therefore, these 
subjects would unlikely need further monitoring. 
 For the subjects that seem like they will not have a pCR, DOT can further monitor 
at week 2 to check for a pCR status.  Also, we can compare the DOT values to the linear 
regressions of the static data and estimate the RCB score at each time point.  Further 
analysis would be needed to determine specifically the RCB-III subjects (subjects with no 
response) since the aforementioned study had only 6 subjects in this group. 
8.2.7 Multi-Center Clinical Trials 
 The NACT DOT imaging study is considered a Phase II clinical trial, where a set 
of subjects are studied for an initial analysis of an experimental imaging system.  The next 
step would be to go to a Phase III clinical study where there would be multiple imaging 
systems and collaborators at other institutions or hospitals involved.  The advantage of 
this study is threefold.  First, this would give us a different subject population that we were 
not capable of reaching at New York Presbyterian Hospital, which would valuable to know 
if the imaging system could work on this subject population as well.   Second, that the 
imaging system is user independent and that similar results could be obtained from 
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different locations, which would show the consistency of the system.  Last, patients could 
be recruited regularly and would yield a much bigger data set than a single center study. 
 Organizing and performing a successful multi-center trial could yield results that 
could help obtain FDA approval and ultimately allow for clinicians to use the DOT system 
within the hospital to help monitor breast cancer. 
8.2.8 Modelling Hemodynamic Trends 
 Now that we have developed a method to acquire and analyze the hemodynamic 
traces from the breath hold imaging, we can look at ways to model these trends.  As I 
have looked at these breath hold traces, I have noticed a variety of differences among 
the curves.  Yet, we do not understand fully what causes these different features to occur.  
Therefore, by modelling theses traces using mock circuit designs, such as the Windkessel 
model, we can possibly mimic the trends occurring in the vasculature and come to a better 
understanding of the physiology.  Last, once we have developed these models, we can 
use them as another method to predict the outcome of NACT based on the resistance or 
capacitance of different sections of the model. 
8.2.9 Additional Data Analysis 
 Due to the large quantity of data, there is still data that needs to be processed.  For 
example, the dynamic data for all time points must still be reconstructed and analyzed to 
view any possible trends in the hemodynamics over time.  Additionally, discriminant 
analysis can be performed on all time points and prediction models could be developed. 
 
8.3 Conclusion 
   137 
 
 Both the optical properties and hemodynamic trends of breast tumors can indicate 
how a patient will respond to NACT.  Additionally, DDOT can easily be employed to safely 
and inexpensively image a patient several times over the course of treatment and their 
tumors can be monitored throughout each stage.  We have observed that the 
%Δ[HbO2](T/nT) correlates with the RCB score of the patient population at each imaging 
time point.  The dynamic study shows that there is an increase in rise slope, fall slope, 
and washout rate in pCR subjects by week 2, which could be explained by the increase 
in blood flow due to the apoptosis of the tumor and decrease of IFP.  Additionally, 
combining the static and dynamic data, we have developed prediction models that are 
capable of predicting the response of the subject at the week 2 imaging time point with 
an accuracy of 94.1%.  Therefore, DDOT static and dynamic capabilities can be utilized 
to observe malignant tumors, predict treatment outcome, and monitor tumor response 
throughout NACT.  As a result, DDOT is a viable imaging modality for an area of breast 
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